



Nocturnal asthma is affected by genetic interactions between RORA and NPSR1

DOI:

[10.1002/ppul.24292](https://doi.org/10.1002/ppul.24292)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Curtin, J., & et al (2019). Nocturnal asthma is affected by genetic interactions between RORA and NPSR1. *Pediatric Pulmonology*. <https://doi.org/10.1002/ppul.24292>

Published in:

Pediatric Pulmonology

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



1 Nocturnal asthma is affected by genetic interactions between *RORA* and *NPSRI*

2
3
4 Vincent D. Gaertner B.Sc.¹, Sven Michel PhD¹, John A. Curtin PhD², Ville Pulkkinen PhD³,
5 Nathalie Acevedo PhD^{4,5}, Cilla Söderhäll PhD^{6,7}, Andrea von Berg MD⁸, Albrecht Bufe MD⁹,
6 Otto Laub MD¹⁰, Ernst Rietschel MD¹¹, Andrea Heinzmann MD¹², Burkhard Simma MD¹³,
7 Christian Vogelberg MD¹⁴, Göran Pershagen PhD¹⁵, Erik Melén PhD^{15,16}, Angela Simpson
8 PhD², Adnan Custovic PhD¹⁷, Juha Kere PhD^{6,18}, and Michael Kabesch MD^{1*}

9
10 ¹ University Children's Hospital Regensburg (KUNO), Department of Pediatric Pneumology
11 and Allergy, Regensburg, Germany

12 ² Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences,
13 The University of Manchester, Manchester Academic Health Science Centre, and Manchester
14 University NHS Foundation Trust, Manchester, UK

15 ³ Heart and Lung Center, Division of Pulmonary Medicine, University of Helsinki and
16 Helsinki University Central Hospital, Helsinki, Finland

17 ⁴ Department of Clinical Science and Education, Karolinska Institutet, Sweden

18 ⁵ Institute for Immunological Research. University of Cartagena, Cartagena, Colombia

19 ⁶ Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

20 ⁷ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

21 ⁸ Research Institute for the Prevention of Allergic Diseases, Children's Department, Marien-
22 Hospital, Wesel, Germany

23 ⁹ Department of Experimental Pneumology, Ruhr-University, Bochum, Germany

24 ¹⁰ Kinder- und Jugendarztpraxis Laub, Rosenheim, Germany

25 ¹¹ University Children's Hospital, Faculty of Medicine, University of Cologne, Cologne,
26 Germany

27 ¹² Center for Pediatrics, Department of General Pediatrics, Adolescent Medicine and
28 Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, University of
29 Freiburg, Germany

30 ¹³ Children's Department, University Teaching Hospital, Landeskrankenhaus Feldkirch,
31 Feldkirch, Austria

32 ¹⁴ University Children's Hospital, Technical University Dresden, Dresden, Germany

33 ¹⁵ Institute of Environmental Medicine, Karolinska Institutet and Centre for Occupational and
34 Environmental Medicine, Stockholm County Council, Stockholm, Sweden

35 ¹⁶ Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden

36 ¹⁷ Department of Paediatrics, Imperial College, London, UK

37 ¹⁸ Research Programs Unit, Program for Molecular Neurology, University of Helsinki, and
38 Folkhälsan Institute of Genetics, Helsinki, Finland

39 ¹⁹ School of Basic & Medical Biosciences, King's College London, London, England

40
41
42 *Corresponding author:

43 Michael Kabesch

44 Steinmetzstr. 1-3

45 93047 Regensburg, Germany

46 Tel: +49-941-3695901

47 E-mail: michael.kabesch@ukr.de (MK)

48

49 Funding: This work was funded by the German Lung Research Center (DZL), Swedish
50 Research Council, the Distinguished Professor Award at Karolinska Institutet to JK, and the
51 Sigrid Jusélius Foundation. BAMSE was supported by the Swedish Research Council, the
52 Swedish Heart-Lung Foundation and the Swedish Research Council Formas. MAAS was
53 supported by Asthma UK Grants No 301 (1995-1998), No 362 (1998-2001), No 01/012
54 (2001-2004), No 04/014 (2004-2007), BMA James Trust (2005) and The JP Moulton
55 Charitable Foundation (2004-current), The North west Lung Centre Charity (1997-current)
56 and the Medical Research Council (MRC) G0601361 (2007-2012), MR/K002449/1 (2013-
57 2014) and MR/L012693/1 (2014-2018). The funding sources had no role in the study design;
58 the collection, analysis and interpretation of data; the writing of the report; and in the decision
59 to submit the article for publication.

60

61 Conflicts of interest: AC received personal fees from Novartis, Regeneron/Sanofi, ALK,
62 ThermoFisher, Boehringer Ingelheim, Novartis, Philips, all outside the submitted work. AS
63 reports grants from Medical Research Council and from the National Institute of Health
64 Research during the conduct of the study. MK received personal fees for lectures from ERS,
65 EAACI, ATS, Novartis, Glaxo, Nutricia, and Hipp as well as research grants from the
66 European Union, the German Ministry of Education and Research, and the German Research
67 Foundation. VDG received travel fees for lectures from the European Academy of Allergy
68 and Clinical Immunology (EAACI). All other authors report no conflict of interest.

69

70 Short title: *RORA* and *NPSRI* affect nocturnal asthma

71 Keywords: nighttime asthma, childhood asthma, genetic epistasis, circadian rhythm

72

74 **Abstract**

75 Background: *Neuropeptide S Receptor 1 (NPSRI)* and *Retinoid Acid Receptor-Related Orphan*
76 *Receptor Alpha (RORA)* interact biologically, are both known candidate genes for asthma and
77 are involved in controlling circadian rhythm. Thus, we assessed (1) whether interactions
78 between *RORA* and *NPSRI* specifically affect the nocturnal asthma phenotype and (2) how this
79 may differ from other asthma phenotypes.

80 Methods: Interaction effects between 24 SNPs in *RORA* and 35 SNPs in *NPSRI* on asthma and
81 nocturnal asthma symptoms were determined in 1,432 subjects [763 asthmatics (192 with
82 nocturnal asthma symptoms); 669 controls] from the MAGIC/ISAAC studies. The results
83 were validated and extended in children from MAAS (N=723) and the BAMSE cohort
84 (N=1,646).

85 Results: *RORA***NPSRI* interactions seemed to affect both asthma and nocturnal asthma. In
86 stratified analyses, however, interactions mainly affected nocturnal asthma and less so asthma
87 without nocturnal symptoms or asthma severity. Results were replicated in two independent
88 cohorts and seemed to remain constant over time throughout youth.

89 Conclusion: *RORA***NPSRI* interactions appear to be involved in mechanisms specific for
90 nocturnal asthma. In contrast to previous studies focusing on the role of beta 2 receptor
91 polymorphisms in nocturnal asthma as a feature of asthma control or severity in general, our
92 data suggests that changes in circadian rhythm control are associated with night-time asthma
93 symptoms.

94

95 Word count Abstract: 210/250

96

97 Word count main text: 3494/3500

98 **Abbreviations**

| | | |
|-----|--------------|-------------------------------------------------------------------|
| 99 | BAMSE | Children Allergy Milieu Stockholm an Epidemiological study |
| 100 | CI | Confidence Interval |
| 101 | DPY19L1 | DPY19 like C-mannosyltransferase 1 |
| 102 | GATA3 | GATA binding protein 3 |
| 103 | GWAS | Genome-wide association study |
| 104 | HWE | Hardy-Weinberg Equilibrium |
| 105 | <i>IL4</i> | Interleukin 4 gene |
| 106 | <i>IL5</i> | Interleukin 5 gene |
| 107 | <i>IL13</i> | Interleukin 13 gene |
| 108 | ISAAC II | International Study of Asthma and Allergies in Childhood phase II |
| 109 | LD | Linkage Disequilibrium |
| 110 | MAGIC | Multicenter Asthma Genetic in Childhood |
| 111 | NPS | Neuropeptide S |
| 112 | <i>NPSR1</i> | Neuropeptide S Receptor 1 gene |
| 113 | OR | Odds Ratio |
| 114 | P300 | Histone acetyltransferase p300 |
| 115 | QC | Quality control |
| 116 | <i>RORA</i> | Retinoic acid receptor-related Orphan Receptor Alpha gene |
| 117 | Rs | Reference SNP cluster code (dbSNP) |
| 118 | SNP | Single Nucleotide Polymorphism |
| 119 | STAT3 | Signal transducer and activator of transcription 3 |

120 INTRODUCTION

121 Nocturnal asthma is defined as night-time occurrence of asthmatic symptoms such as wheezing,
122 coughing, or chest tightness ^{1,2}. Between 30 and 75% of asthma patients experience these
123 symptoms ³⁻⁵. It is known that the circadian rhythm controls airway inflammation, vagal
124 activity, and epinephrine release ⁶, thus potentially aggravating asthma symptoms during the
125 night ^{6,7}. Nocturnal asthma may either be a feature related to asthma severity or alternatively, it
126 may be a subphenotype of the disease, associated with the presence of specific and unique
127 molecular patterns ⁸. This goes along with the current understanding that asthma is not a
128 homogenous and uniform disease but rather, a syndrome to which different mechanisms may
129 contribute in individuals and specific group of patients.

130

131 Interestingly, two candidate genes for asthma, *NPSRI* (chromosome 7p14.3) and *RORA*
132 (chromosome 15q22.2), have recently been suggested to play a role in controlling circadian
133 rhythm ⁹⁻¹¹. *NPSRI*, a G protein-coupled receptor, has been associated to asthma susceptibility
134 in numerous studies ¹²⁻¹⁴, while also having been related to the circadian rhythm in mice and
135 humans ^{9,15}. *RORA*, a nuclear hormone receptor, was associated with asthma ^{16,17} and its mRNA
136 expression varies during human lung development and during murine lung inflammation ^{11,18-}
137 ²⁰. Also, *RORA* is known to influence the circadian rhythm of various physiological processes
138 ^{11,18-22}. Finally, it was recently suggested that *RORA* and *NPSRI* interact biologically by
139 influencing promoter activity and each other's gene expression thereby modifying asthma risk
140 concomitantly ²³.

141

142 We hypothesized that through their effects on circadian rhythm and asthma, *RORA* and *NPSRI*
143 would specifically influence nocturnal asthma. Thus, the aims of this study were (1) to

144 investigate whether gene-gene-interactions between *RORA* and *NPSRI* specifically affect the
145 occurrence of nocturnal asthma and (2) to differentiate these effects from asthma without
146 nocturnal symptoms or severe asthma.

147 **MATERIALS AND METHODS**

148 **Study populations**

149 As a discovery population in a case reference design we investigated participants from the
150 Multicenter Asthma Genetic in Childhood study (MAGICS) and the cross-sectional
151 International Study of Asthma and Allergies in Childhood phase II (ISAAC II) as previously
152 described in the first GWAS on asthma (N=1,454)²⁴. Replication was carried out in two
153 population-based birth cohorts: BAMSE (Children Allergy Milieu Stockholm Epidemiology
154 study; N=2,033) from Sweden and MAAS (Manchester Asthma and Allergy Study; N=1085)
155 from the UK. Study populations have been described elsewhere²⁴⁻²⁷. The studies were
156 approved by the respective ethics committees. Written informed consent was obtained from all
157 parents.

158

159 **Phenotypes**

160 In MAGICS, asthma was diagnosed by a pediatric pulmonologist based on clinical presentation
161 and objective measures including lung function and allergy tests. In ISAAC II and BAMSE, a
162 parentally reported physician's diagnosis had to be present while in MAAS children with at
163 least two out of three features [(1) Wheezing or whistling in the chest in the last 12 months; (2)
164 Current use of asthma medication; (3) Physician-diagnosed asthma ever] were compared to
165 children with 0/3 features.

166

167 Nocturnal asthma was defined as asthma plus parentally reported wheezing or gasping during
168 the night at least once over the previous 12 months in MAGICS/ISAAC and MAAS. In BAMSE,
169 asthma plus any coughing or breathing difficulties throughout the night sufficed. Due to this

170 slight disparity, phenotypes were denominated differently: *nocturnal asthma symptoms*
171 (MAGICS/ISAAC and MAAS) and *nocturnal breathing difficulties* (BAMSE). In MAAS,
172 phenotypes were also assessed at 16 years. Figure 1 displays the number of patients in each
173 group. Subjects with neither asthma nor nocturnal symptoms served as controls in all cohorts.

174

175 Asthma severity is not unanimously defined and it was thus assessed differently in all cohorts:
176 in MAGICS/ISAAC, the number of hospital, emergency department or doctor visits due to
177 asthmatic symptoms was counted; in MAAS, the number of exacerbations over twelve months
178 were counted; and in BAMSE, nighttime wheezing, the use of asthma medication and activity
179 limitation were assessed. Asthma severity was assessed as a continuous variable within the
180 asthmatic cases only.

181

182 **Functional database scan**

183 Functional databases (HaploReg, SNPinfo, SNIIPA, ENCODE, Roadmap Epigenomics project,
184 GRASP database) were systematically screened for functional relevance of associated SNPs.
185 Sequence conservation analyses were based on SiPhy and GERP elements. Regulatory protein
186 binding was obtained from the ENCODE ChIP-Seq data, epigenomic data from the Roadmap
187 Epigenomics project and eQTL from GTEx and the GRASP database.

188 For study design, SNP selection and genotyping details please refer to the online supplement.

189

190 **Statistical analysis**

191 Associations of binary traits were evaluated by logistic regression, interactions were assessed
192 using the --epistasis command and deviation from Hardy-Weinberg equilibrium was analyzed
193 by chi-square test in the control group, all using PLINK 1.0.7²⁸. All further analyses were

194 performed with R software (3.0.1; <http://www.r-project.org/>). All markers were in HWE
195 ($p > 0.0001$). Odds ratios (OR) and 95% confidence intervals (CI) are reported for dichotomous
196 variables and beta-values and standard errors (SE) for continuous variables. We present ORs
197 and beta-values instead of providing figures for every single interaction for a better readability
198 and clarity of the text. Linkage Disequilibrium (LD) plots were generated with Haploview²⁹.

199

200 Testing a specific hypothesis, p -values < 0.05 were considered statistically significant for the
201 replication analyses. In order to account for multiple testing in *de novo* interaction analyses and
202 to minimize the risk of reporting false positive results, we only discuss polymorphisms for
203 which the number of significant interactions exceeded stochastic expectation, as suggested
204 previously³⁰. More precisely, polymorphisms had to display at least three significant
205 interactions with SNPs from the respective other gene ($24 \text{ SNPs} * 0.05 = 1.2$ and 35
206 $\text{SNPs} * 0.05 = 1.75 \approx 2$ expected false positive results per SNP).

207 **RESULTS**

208 **Interactions between *RORA* and *NPSRI* SNPs affect the risk for asthma**

209 First, we investigated systematically if gene-gene-interactions between *RORA* and *NPSRI*
210 affect asthma in our MAGICS/ISAAC population. For that we enriched the two gene loci with
211 all SNPs previously associated with asthma, confirming and expanding a previous report by
212 Acevedo, where a smaller number of SNPs were studied in the BAMSE and PARSIFAL cohorts
213 ²³. Indeed, seven SNPs within *RORA* and eight *NPSRI*-SNPs were found to significantly
214 contribute to interactions associated with asthma in MAGICS/ISAAC (Figure 2 and
215 Supplementary Table S2). *RORA* rs12591848 interacted with eight SNPs in *NPSRI* [most
216 strongly with rs1419779; OR(CI)=0.45(0.30-0.68); $p=1.51*10^{-4}$] and *NPSRI* rs963218
217 interacted with nine SNPs in *RORA* [most strongly with rs12591848; OR(CI)=0.51(0.35-0.74);
218 $p=4.60*10^{-4}$]. Of these newly found interactions, we could replicate five interactions in our
219 additional cohorts (including BAMSE where they were not originally reported) and six of the
220 newly found interactions showed a trend towards significance in the replication cohorts.
221 Especially the combination of rs2899662 and rs887020 affected asthma constantly across
222 populations (Table 1 and Supplementary Table S3). Of note, only two combinations of SNPs
223 in each gene were linked with an $r^2>0.80$ (see Supplementary Figures S3 and S4).

224

225 **Interactions between *RORA* and *NPSRI* SNPs affect nocturnal asthma** 226 **symptoms specifically**

227 We then assessed epistasis effects on nocturnal asthma in our discovery population. Overall,
228 twelve *RORA*-SNPs showed at least three significant interactions with SNPs in *NPSRI* in
229 relation to nocturnal asthma. Six of these SNPs were only associated with nocturnal asthma,

230 and not with asthma *per se*. Within *NPSRI*, twelve SNPs showed at least three significant
231 interactions with *RORA* when nocturnal asthma symptoms were the outcome. Seven of these
232 SNPs seemed to represent genuine associations with nocturnal asthma, as they did not interact
233 with *RORA*-SNPs to affect asthma *per se*. The strongest overall signals were noted for
234 rs6972158 in *NPSRI* and rs7171681 in *RORA*, which each interacted significantly with at least
235 ten SNPs from the respective other gene. The strongest single interaction affecting nocturnal
236 asthma symptoms was found for *NPSRI* rs324396 and *RORA* rs7171681 [OR(CI)=0.45(0.28-
237 0.73); p=0.0013] (see Figure 3 and Supplementary Table S5). Taken together, we concluded
238 that indeed numerous gene by gene interactions between *RORA* and *NPSRI* exist and that these
239 may affect nocturnal asthma.

240

241 Now we attempted to replicate the significant results with similar phenotypes in BAMSE and
242 MAAS. Interestingly, we were able to replicate seven interactions in MAAS with six further
243 interactions reaching borderline significance in one of the datasets. Of note, the effect direction
244 was the same in the other replication dataset in most cases (Table 2 and Supplementary Table
245 S6). Particularly the combination of rs324396*rs2899662 and rs13799228*rs4775292 affected
246 nocturnal asthma strongly in all cohorts. To detect temporal continuity we assessed whether
247 interaction effects at age 11 remained associated with nocturnal asthma at age 16 in MAAS.
248 Intriguingly, two out of eleven interactions still affected nocturnal asthma significantly at age
249 16 (rs324396*rs2899662 and rs324396*rs341382) and four interactions reached borderline
250 significance (Supplementary Table S7).

251

252 Finally, we rigorously prioritized associated SNPs based on the number of original interactions
253 (interacting with $\geq 25\%$ of the other gene's SNPs) and the number of replicated interactions (≥ 2

254 replications) to only include our main hits (N=10, see Supplementary Figure S5). Scanning
255 various databases, we found that all but two of our top SNPs are predicted to have relevant
256 functional impact (Table 3): While one SNP (rs6972158) results in a non-conservative amino
257 acid change from glutamine to arginine in *NPSRI*, seven out of the remaining nine SNPs are
258 tightly linked to SNPs predicted to be located in promoter regions and five SNPs alter
259 transcription factor binding sites for various proteins known to play important roles in
260 immunology and chronobiology^{31,32}. In turn, 6 of these SNPs also lead to a differential gene
261 expression in tested tissues. Of note, 3 of these SNPs are located in phylogenetically highly
262 conserved regions.

263

264 ***RORA* and *NPSRI* interactions have minor effects on asthma without** 265 **nocturnal symptoms**

266 Next, we analysed if *RORA* by *NPSRI* interactions affect asthmatics without nocturnal asthma
267 symptoms. If *RORA* by *NPSRI* interactions were involved in a mechanism specific for
268 nocturnal asthma, associations in asthmatics *without* nocturnal symptoms would be expected to
269 be absent or much weaker than the ones found in asthmatics *with* nocturnal symptoms. Indeed,
270 there were fewer interactions associated with the occurrence of asthma without nocturnal
271 symptoms: only four *NPSRI*-SNPs interacted with ≥ 3 *RORA*-SNPs and only two *RORA*-SNPs
272 interacted with ≥ 3 SNPs in *NPSRI*. The strongest interaction was noted for *NPSRI* rs323917*
273 *RORA* rs17204454 [OR(CI)=0.29(0.13-0.61); $p=0.0012$]. We could replicate one interaction in
274 BAMSE and most interactions had the same effect direction (Supplementary Tables S8 and
275 S9). In comparison, as seen above, there was a total of 24 SNPs from both genes interacting
276 with ≥ 3 SNPs from the respective other gene when asthma *with* nocturnal symptoms was the

277 outcome. Results of these analyses are displayed in a comparative manner in Figure 3. Of note,
278 atopy status in asthmatics (71.8%) and nocturnal asthmatics (74.0%) was comparable.

279

280 **Effects of *RORA* and *NPSRI* interactions on asthma severity**

281 To further disentangle whether *RORA* and *NPSRI* specifically affect nocturnal asthma we also
282 sought to describe the two genes' effects on asthma severity in our three populations, even
283 though one has to be aware that severity definitions varied somewhat between these studies (as
284 described in the methods section). This analysis was based on the assumption that the effects
285 on nocturnal asthma may be influenced and/or partly explained by asthma severity. We could
286 show that seven *RORA*-SNPs as well as nine *NPSRI*-SNPs interacted with ≥ 3 SNPs from the
287 respective other gene to associate with asthma severity (Supplementary Figure S2). Overall,
288 there were 52 significant interactions [strongest interaction rs2530547*rs4775289:
289 $\beta(\text{SE})=0.53(0.14)$, $p=0.0002$]. Some of these interactions had also affected nocturnal asthma,
290 thus implying that their effect on nocturnal asthma and on asthma severity may be confounded.
291 However, most interactions between *RORA* and *NPSRI* remained specific for nocturnal asthma.
292 Lastly, four SNPs in *RORA* as well as three *NPSRI*-SNPs seemed to be only associated with
293 asthma severity and not nocturnal asthma. However, when trying to replicate our results in the
294 two independent cohorts, we found that almost no interaction had the same effect direction in
295 both replication cohorts for severity, very much in contrast to our constant replications for
296 nocturnal asthma across different cohorts (Supplementary Table S11).

297

298 **DISCUSSION**

299 This study deciphers a plausible genetic mechanism for nocturnal asthma by demonstrating that
300 interactions between *RORA* and *NPSRI* are specifically associated with nocturnal asthma,
301 suggesting the involvement of a genetic mechanism related to circadian rhythm control.

302

303 We replicated and extended recent observations that interactions between *RORA* and *NPSRI*
304 increase the risk to develop asthma in three independent cohorts. By systematically enriching
305 both *RORA* and *NPSRI* gene loci we identified a number of additional and novel gene-gene-
306 interactions driving asthma. The most intriguing and novel result from our study, however, is
307 that interactions between *RORA* and *NPSRI* strongly associate with nocturnal asthma, rather
308 than asthma *per se*. There has been limited evidence for a genetic background of nocturnal
309 asthma, all relating to the beta2 adrenoreceptor (*ADRB2*), coming from rather small datasets
310 ³³⁻³⁵. These studies followed the hypothesis that mutations in *ADRB2* increase airway
311 constriction in asthmatics and reduce the response to treatment, thus increasing symptoms and
312 severity, possibly even pronounced at night. Our study now shows a mechanism specific for
313 nocturnal symptoms by deciphering molecular associations within genes of the circadian
314 rhythm: As both genes under investigation have been independently associated with asthma
315 susceptibility ^{12-14,16,23} and seem to play a role in defining the circadian rhythm ^{15,18}, the
316 observed associations are biologically plausible.

317

318 There are some limitations to our study: Firstly, it has to be acknowledged that this was a
319 retrospective study design with questionnaire-based definitions of nocturnal symptoms as well
320 as asthma severity. This may have led to an under-estimation of the number of nocturnal
321 asthmatics, possibly indicated by the low number of nocturnal asthmatics in our study. This

322 may potentially have skewed the results. However, a failure to assign some of the nocturnal
323 asthmatics to any respective group would normally lead to an under-estimation of the power of
324 any found difference, thereby potentially even under-estimating the actual effect size. Secondly,
325 we tested a number of independent associations, thus raising the issue of multiple testing. We
326 tried to avoid false-positive results by focusing on polymorphisms for which the number of
327 significant interactions exceeded the stochastic expectation ³⁰. Considering only SNPs that
328 showed ≥ 3 interactions reduced (but did not exclude) the probability of obtaining false-positive
329 results. For interaction analyses it is biologically plausible that SNPs would interact with
330 several SNPs from the respective other gene if they have impact on function ²³.

331

332 Intriguingly, we were able to replicate several interactions in MAAS even though replication
333 of interaction analyses is only rarely achieved ³⁶. Replication analyses with the phenotype
334 *nocturnal breathing difficulties* in BAMSE did not reach significance. This may partly be due
335 to the difference in phenotypes: In MAGICS/ISAAC and MAAS, the phenotype was relatively
336 specific for asthma as it asked for nocturnal wheezing or gasping. In BAMSE, however, parents
337 were asked for general coughing and breathing difficulties at night which is less specific for
338 asthma. This could also explain why in BAMSE 307 children showed nocturnal breathing
339 difficulties without having asthma, while only 14 children in MAGICS/ISAAC and no child in
340 MAAS reported nocturnal symptoms without an asthma diagnosis. However, even in BAMSE,
341 effect directions were the same for almost all interactions. The constant replication and the
342 extension to nocturnal asthma at age 16 in MAAS implies (1) that this is a mechanism specific
343 for nocturnal asthma and (2) that this mechanism is stable over populations and over time. The
344 stability of these findings is intriguing, as replication of interaction effects is difficult to achieve
345 ³⁶. To find and replicate interactions despite our relatively small sample sizes of approximately

346 1,000-1,500 individuals in each dataset implies a strong effect size of these interactions, indeed
347 indicated by relatively high odds ratios. A further strength of our study is the clinically defined
348 asthma phenotype that was largely obtained by a pediatric pulmonologist rather than by parental
349 report.

350

351 To assess whether these results are explained by the similarity between nocturnal asthma and
352 severe asthma we compared *RORA* by *NPSR1* effects on asthma severity with our findings on
353 nocturnal asthma. However, it has to be noted that this analysis was performed to differentiate
354 nocturnal asthma from severe asthma and should only be interpreted in relation to nocturnal
355 asthma results. We found that the two genes also interact in affecting asthma severity in
356 MAGICS/ISAAC but could not replicate these results in MAAS or BAMSE. The inability to
357 replicate results on this phenotype may be due to different definitions of asthma severity in the
358 three datasets, reflecting the ambiguity of this phenotype. There are several clinical features
359 that contribute to asthma severity, thus making it difficult to comprehensively investigate this
360 phenotype. As nighttime awakenings are sometimes regarded as a feature of asthma severity, it
361 is not yet understood to what extent nocturnal asthma is an independent phenotype. Thus, we
362 sought to discriminate the effect of *RORA* and *NPSR1* on nocturnal asthma and on asthma
363 severity. Based on our data it seems as if nocturnal asthma and asthma severity are related but
364 distinct features of asthma. However, we cannot draw final conclusions due to our failed
365 replications and the ambiguous phenotypes.

366

367 The NPS/NPSR1 system as well as *RORA* have been shown to play a role in circadian rhythm:
368 *NPSR* knockout mice exhibited lower activity levels under light-dark conditions, NPS
369 injections lead to an increased wakefulness and non-synonymous *NPSR1* rs324981 was

370 recently associated with a delay of bedtime and sleep duration ^{9,10,15}. *RORA* gene expression
371 varies throughout the day and *Rora*-deficient mice showed a decreased activity and could not
372 adjust to light-dark cycles ^{18,21,23}. Additionally, *RORA* modulates the rhythmic expression of
373 downstream target genes, which were recently implicated in mast cell cytokine secretion ³⁷ and
374 lung epithelial chemokine production ³⁸, thereby connecting circadian rhythm genes with
375 immunological processes ^{11,18-22}. Interestingly, *NPSRI*-overexpressing cells demonstrated an
376 increased mRNA expression of *RORA* and other circadian genes ^{23,39} and *in vivo Npsr1*-
377 deficient mice showed a lower *RORA* mRNA expression ²³. Reversely, it was shown that *RORA*
378 regulates *NPSRI* promoter activity ²³. Taken together, both *RORA* and *NPS/NPSRI* signalling
379 appear to be interwoven when acting upon complex immune-related circadian outcomes, and
380 in our case nocturnal asthma.

381
382 By systematically scanning online databases for functional relevance of our main hits we found
383 that 8 out of 10 (or their proxy-SNPs in high LD) are predicted to have functional effects:
384 rs6972158 is a missense SNP resulting in an amino-acid change from glutamine to arginine at
385 position 344 of the isoform A of NPSR1. Gln344 is located within the cytosolic domain of the
386 NPSR1 protein and hence, it could have an effect on intracellular signaling. Future *in vitro*
387 studies should address whether allele specific effects of rs6972158 influence transcription rates
388 of genes involved in the inflammatory response or the molecular clock in lung tissue.

389
390 Interestingly, seven out of the remaining nine SNPs are tightly linked to SNPs predicted to be
391 located in promoter regions ⁴⁰, and known to be binding sites for protein playing an important
392 role in immunology and chronobiology: GATA3 induces IL-4, IL-5 and IL-13 secretion and is
393 strongly involved in asthma susceptibility ^{32,41} and P300 is an important part of the circadian

394 clock ⁴². Most interestingly, four of our investigated top hits were in tight relation to STAT3
395 gene expression or showed differential binding capabilities for this relevant transcription factor:
396 Up-regulation of STAT3 is associated with lung inflammation as well as an altered cytokine
397 profile in asthmatic patients ³¹. Additionally, it is known to dynamically control Th2 and Th17
398 cell responses during allergic lung inflammation in mice and humans ³¹ while being
399 rhythmically expressed and triggered by the endogenous clock ⁴³. Furthermore, *NPSRI*
400 rs1379928, rs1419779 and rs6972158 as well as *RORA* rs2899662, rs4775301 and rs341382
401 have been shown to increase downstream gene expression while *RORA* rs2899662 and
402 rs7171681 are linked to mono- or tri-methylated histone mark H3K4 in T-helper cells, thus
403 promoting downstream gene expression ⁴⁰. Therefore, new starting points for functional
404 genomic assessments have been identified.

405

406 All in all, major SNPs showing association in interaction analyses in this study seem to be
407 highly relevant for lung inflammation and asthma susceptibility while at the same time being
408 involved in the circadian rhythm by promoting gene expression differentially. However, to
409 conclusively determine biological plausibility of the results, further prospective and
410 mechanistic studies are needed. Thus, it might be worthwhile to study the influence of further
411 circadian rhythm genes on nocturnal asthma, potentially also investigating mitigation by the
412 sympathetic nervous system. Understanding the pathogenesis of nocturnal asthma could
413 increase our clinical and causal knowledge of the disease, thus potentially impacting on
414 improvements in management and care for the affected patients.

415

416 Taking all aspects into account, we conclude that *RORA* and *NPSRI* interactions are consistent
417 and that these interactions are mainly associated with the development of nocturnal asthma, an

418 association which is not only statistically significant but biologically plausible due to the role
419 of both genes in asthma and circadian rhythm. Our data implies that nocturnal asthma is no
420 simple disease entity in the severity spectrum of the disease. Specific molecular patterns
421 regulating the circadian clock, such as those studied here, are associated with nighttime
422 symptoms. Further research could help to clarify mechanisms and introduce potential avenues
423 of intervention in this subphenotype of asthma that is not well understood but highly
424 troublesome for patients.

425

426

427 **ACKNOWLEDGEMENTS**

428 We thank all participants of the MAGIC, ISAAC II, MAAS, BAMSE, and PARSIFAL studies.

429 We thank the Mutation Analysis Core Facility (MAF) at the Karolinska University Hospital for
430 their support with this work.

431

433

434 **REFERENCES**435 1. Sutherland ER. Nocturnal asthma. *The Journal of allergy and clinical immunology*.

436 2005;116(6):1179–86. doi:10.1016/j.jaci.2005.09.028

437 2. Ginsberg D. An unidentified monster in the bed - assessing nocturnal asthma in children.

438 *McGill journal of medicine : MJM : an international forum for the advancement of medical*439 *sciences by students*. 2009;12(1):31–8.

440 3. Meijer GG, Postma DS, Wempe JB, Gerritsen J, Knol K, van Aalderen WM. Frequency of

441 nocturnal symptoms in asthmatic children attending a hospital out-patient clinic. *The*442 *European respiratory journal*. 1995;8(12):2076–80.

443 4. Raheison C, Abouelfath A, Le Gros V, Taytard A, Molimard M. Underdiagnosis of

444 nocturnal symptoms in asthma in general practice. *The Journal of asthma: official journal of*445 *the Association for the Care of Asthma*. 2006;43(3):199–202.

446 doi:10.1080/02770900600566744

447 5. Chugh IM, Khanna P, Shah A. Nocturnal symptoms and sleep disturbances in clinically

448 stable asthmatic children. *Asian Pacific journal of allergy and immunology*. 2006;24(2–

449 3):135–42.

450 6. Burioka N, Fukuoka Y, Koyanagi S, Miyata M, Takata M, Chikumi H, Takane H,

451 Watanabe M, Endo M, Sako T, et al. Asthma: Chronopharmacotherapy and the molecular

452 clock. *Advanced Drug Delivery Reviews*. 2010;62(9–10):946–955.

453 doi:10.1016/j.addr.2010.03.012

454 7. Kraft M, Martin RJ, Wilson S, Djukanovic R, Holgate ST. Lymphocyte and eosinophil

455 influx into alveolar tissue in nocturnal asthma. *American journal of respiratory and critical*456 *care medicine*. 1999;159(1):228–34. doi:10.1164/ajrccm.159.1.9804033

- 457 8. Calhoun WJ. Nocturnal asthma. *Chest*. 2003;123(3 Suppl):399S–405S.
- 458 9. Duangdao DM, Clark SD, Okamura N, Reinscheid RK. Behavioral phenotyping of
459 Neuropeptide S receptor knockout mice. *Behavioural Brain Research*. 2009;205(1):1–9.
460 doi:10.1016/j.bbr.2009.07.024
- 461 10. Zhao P, Shao YF, Zhang M, Fan K, Kong XP, Wang R, Hou YP. Neuropeptide S
462 promotes wakefulness through activation of the posterior hypothalamic histaminergic and
463 orexinergic neurons. *Neuroscience*. 2012;207:218–226.
464 doi:10.1016/j.neuroscience.2012.01.022
- 465 11. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development,
466 immunity, circadian rhythm, and cellular metabolism. *Nuclear Receptor Signaling*. 2007;4.
467 doi:10.1621/nrs.07003
- 468 12. Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, Mäkelä S, Rehn
469 M, Pirskanen A, Rautanen A, et al. Characterization of a common susceptibility locus for
470 asthma-related traits. *Science (New York, N.Y.)*. 2004;304(5668):300–4.
471 doi:10.1126/science.1090010
- 472 13. Melén E, Bruce S, Doekes G, Kabesch M, Laitinen T, Lauener R, Lindgren CM, Riedler
473 J, Scheynius A, van Hage-Hamsten M, et al. Haplotypes of G Protein–coupled Receptor 154
474 Are Associated with Childhood Allergy and Asthma. *American Journal of Respiratory and
475 Critical Care Medicine*. 2005;171(10):1089–1095. doi:10.1164/rccm.200410-1317OC
- 476 14. Kormann MSD, Carr D, Klopp N, Illig T, Leupold W, Fritzscher C, Weiland SK, von
477 Mutius E, Kabesch M. G-Protein-coupled receptor polymorphisms are associated with asthma
478 in a large German population. *American journal of respiratory and critical care medicine*.
479 2005;171(12):1358–62. doi:10.1164/rccm.200410-1312OC
- 480 15. Spada J, Sander C, Burkhardt R, Häntzsch M, Mergl R, Scholz M, Hegerl U, Hensch T.

- 481 Genetic association of objective sleep phenotypes with a functional polymorphism in the
482 neuropeptide S receptor gene. *PloS one*. 2014;9(6):e98789.
483 doi:10.1371/journal.pone.0098789
- 484 16. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E,
485 Farrall M, Lathrop M, Cookson WOCM, et al. A large-scale, consortium-based genomewide
486 association study of asthma. *The New England journal of medicine*. 2010;363(13):1211–21.
487 doi:10.1056/NEJMoa0906312
- 488 17. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE,
489 Himes BE, Levin AM, Mathias RA, Hancock DB, et al. Meta-analysis of genome-wide
490 association studies of asthma in ethnically diverse North American populations. *Nature*
491 *genetics*. 2011;43(9):887–92.
- 492 18. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, Naik KA, FitzGerald
493 GA, Kay SA, Hogenesch JB. A functional genomics strategy reveals Rora as a component of
494 the mammalian circadian clock. *Neuron*. 2004;43(4):527–37.
495 doi:10.1016/j.neuron.2004.07.018
- 496 19. Kang HS, Angers M, Beak JY, Wu X, Gimble JM, Wada T, Xie W, Collins JB, Grissom
497 SF, Jetten AM. Gene expression profiling reveals a regulatory role for ROR alpha and ROR
498 gamma in phase I and phase II metabolism. *Physiological genomics*. 2007;31(2):281–94.
499 doi:10.1152/physiolgenomics.00098.2007
- 500 20. Melén E, Kho AT, Sharma S, Gaedigk R, Leeder JS, Mariani TJ, Carey VJ, Weiss ST,
501 Tantisira KG. Expression analysis of asthma candidate genes during human and murine lung
502 development. *Respiratory research*. 2011;12:86. doi:10.1186/1465-9921-12-86
- 503 21. Akashi M, Takumi T. The orphan nuclear receptor RORalpha regulates circadian
504 transcription of the mammalian core-clock *Bmal1*. *Nature structural & molecular biology*.

- 505 2005;12(5):441–8. doi:10.1038/nsmb925
- 506 22. Guillaumond F, Dardente H, Giguère V, Cermakian N. Differential control of Bmal1
507 circadian transcription by REV-ERB and ROR nuclear receptors. *Journal of biological*
508 *rhythms*. 2005;20(5):391–403. doi:10.1177/0748730405277232
- 509 23. Acevedo N, Sääf A, Söderhäll C, Melén E, Mandelin J, Pietras CO, Ezer S, Karisola P,
510 Vendelin J, Gennäs GB af, et al. Interaction between retinoid acid receptor-related orphan
511 receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma. *PloS one*.
512 2013;8(4):e60111. doi:10.1371/journal.pone.0060111
- 513 24. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg
514 A, Bufe A, Rietschel E, et al. Genetic variants regulating ORMDL3 expression contribute to
515 the risk of childhood asthma. *Nature*. 2007;448(7152):470–3. doi:10.1038/nature06014
- 516 25. Kull I, Melen E, Alm J, Hallberg J, Svartengren M, van Hage M, Pershagen G, Wickman
517 M, Bergström A. Breast-feeding in relation to asthma, lung function, and sensitization in
518 young schoolchildren. *The Journal of allergy and clinical immunology*. 2010;125(5):1013–9.
519 doi:10.1016/j.jaci.2010.01.051
- 520 26. Custovic A, Simpson BM, Murray CS, Lowe L, Woodcock A, NAC Manchester Asthma
521 and Allergy Study Group. The National Asthma Campaign Manchester Asthma and Allergy
522 Study. *Pediatric allergy and immunology: official publication of the European Society of*
523 *Pediatric Allergy and Immunology*. 2002;13 Suppl 15:32–7.
- 524 27. Michel S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, Schedel M, Vogelberg C,
525 von Mutius E, von Berg A, et al. Unifying candidate gene and GWAS Approaches in Asthma.
526 *PloS one*. 2010;5(11):e13894. doi:10.1371/journal.pone.0013894
- 527 28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar
528 P, de Bakker PIW, Daly MJ, et al. PLINK: a tool set for whole-genome association and

- 529 population-based linkage analyses. *American journal of human genetics*. 2007;81(3):559–75.
530 doi:10.1086/519795
- 531 29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and
532 haplotype maps. *Bioinformatics*. 2005;21(2):263–265. doi:10.1093/bioinformatics/bth457
- 533 30. Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A, Ruschendorf F, Patone
534 G, Rohde K, Marenholz I, Schulz F, Kerscher T, et al. A common variant on chromosome
535 11q13 is associated with atopic dermatitis. *Nature Genetics*. 2009;41(5):596–601.
536 doi:10.1038/ng.347
- 537 31. Levy DE, Lee C. What does Stat3 do? *The Journal of clinical investigation*.
538 2002;109(9):1143–8. doi:10.1172/JCI15650
- 539 32. Krug N, Hohlfeld JM, Kirsten A-M, Kornmann O, Beeh KM, Kappeler D, Korn S,
540 Ignatenko S, Timmer W, Rogon C, et al. Allergen-Induced Asthmatic Responses Modified by
541 a GATA3-Specific DNase. *New England Journal of Medicine*. 2015;372(21):1987–1995.
542 doi:10.1056/NEJMoa1411776
- 543 33. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta 2-
544 adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates
545 with the nocturnal phenotype. *Journal of Clinical Investigation*. 1995;95(4):1635–1641.
546 doi:10.1172/JCI117838
- 547 34. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between
548 Genetic Polymorphisms of the beta2-Adrenoceptor and Response to Albuterol in Children
549 with and without a History of Wheezing. *Journal of Clinical Investigation*.
550 1997;100(12):3184-3188.
- 551 35. Santillan AA, Camargo CA, Ramirez-Rivera A, Delgado-Enciso I, Rojas-Martinez A,
552 Cantu-Diaz F, Barrera-Saldana HA. Association between beta2-adrenoceptor polymorphisms

- 553 and asthma diagnosis among Mexican adults. *The Journal of allergy and clinical immunology*.
554 2003;112(6):1095–100. doi:10.1016/j.jaci.2003.09.029
- 555 36. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. *Nature*
556 *reviews. Genetics*. 2009;10(6):392–404. doi:10.1038/nrg2579
- 557 37. Christ P, Sowa AS, Froy O, Lorentz A. The Circadian Clock Drives Mast Cell Functions
558 in Allergic Reactions. *Frontiers in immunology*. 2018;9:1526.
559 doi:10.3389/fimmu.2018.01526
- 560 38. Ince LM, Zhang Z, Beesley S, Vonslow RM, Saer BR, Matthews LC, Begley N, Gibbs
561 JE, Ray DW, Loudon ASI. Circadian variation in pulmonary inflammatory responses is
562 independent of rhythmic glucocorticoid signaling in airway epithelial cells. *FASEB journal*:
563 official publication of the Federation of American Societies for Experimental Biology. 2018
564 Jul 2:fj201800026RR. doi:10.1096/fj.201800026RR
- 565 39. Pulkkinen V, Ezer S, Sundman L, Hagström J, Remes S, Söderhäll C, Greco D, Dario G,
566 Haglund C, Kere J, et al. Neuropeptide S receptor 1 (NPSR1) activates cancer-related
567 pathways and is widely expressed in neuroendocrine tumors. *Virchows Archiv: an*
568 *international journal of pathology*. 2014;465(2):173–83. doi:10.1007/s00428-014-1602-x
- 569 40. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell
570 types, regulators and target genes for human complex traits and disease. *Nucleic Acids*
571 *Research*. 2016;44(D1):D877–D881. doi:10.1093/nar/gkv1340
- 572 41. Rayees S, Malik F, Bukhari SI, Singh G. Linking GATA-3 and interleukin-13:
573 implications in asthma. *Inflammation Research*. 2014;63(4):255–265. doi:10.1007/s00011-
574 013-0700-6
- 575 42. Hosoda H, kato K, Asano H, Ito M, Kato H, Iwamoto T, Suzuki A, Masushige S, Kida S.
576 CBP/p300 is a cell type-specific modulator of CLOCK/BMAL1-mediated transcription.

577 Molecular Brain. 2009;2(1):34. doi:10.1186/1756-6606-2-34
578 43. Lech K, Ackermann K, Revell VL, Lao O, Skene DJ, Kayser M. Dissecting Daily and
579 Circadian Expression Rhythms of Clock-Controlled Genes in Human Blood. Journal of
580 Biological Rhythms. 2016;31(1):68–81. doi:10.1177/0748730415611761
581
582

583 FIGURES

584

585 **Figure 1. Schematic depiction of the cohorts and patients involved.** Excluded patients and
586 the reason for exclusion from analyses are written on white background. Grey background
587 indicates included patients. All non-asthmatics served as controls when evaluating the effect of
588 the two genes on asthma and only non-asthmatics without nocturnal symptoms served as
589 controls when the nocturnal phenotypes were the outcome. Thus, patients without information
590 on their nocturnal asthma status were excluded for stratified analyses on the impact of nocturnal
591 symptoms.

592

593 **Figure 2. Heat map of the interaction results of *RORA***NPSRI* on asthma in**
594 **MAGICS/ISAAC.** Color explanation to the right. Darker colors indicate stronger associations.
595 SNPs obtained from the regular GWAS dataset are highlighted in dark grey, imputed SNPs are
596 highlighted in light grey.

597

598 **Figure 3. Heat map of the interaction results of *RORA***NPSRI* on asthma with and asthma**
599 **without nocturnal symptoms in MAGICS/ISAAC.** Color coding is explained on the right.
600 Green colors indicate a significant interaction when asthma with nocturnal symptoms was the
601 outcome whereas orange and red colors indicate a significant interaction when asthma without
602 nocturnal symptoms was the outcome. Cells in yellow mark interactions which are significantly
603 associated with both outcomes. Darker colors indicate a stronger association. SNPs obtained
604 from the regular GWAS dataset are highlighted in dark grey, imputed SNPs are highlighted in
605 light grey.

606

607

Nocturnal asthma is affected by genetic interactions between *RORA* and *NPSRI*

Gaertner et al.

TABLES

Table 1. Significant interaction results (*RORA* * *NPSRI*) on asthma in all cohorts.

| Interaction on asthma ^a | MAGICS/ISAAC | MAAS | BAMSE |
|--------------------------------------------------|----------------------------------|--------------------------------|-------------------------------|
| rs2899662 * rs887020 | 1.34 (1.06-1.7) 0.015 | 1.46 (1.02-2.09) 0.0407 | 1.41 (1.06-1.87) 0.018 |
| rs2899662 * rs963218 | 1.39 (1.1-1.75) 0.006 | 1.29 (0.9-1.83) 0.162 | 1.33 (1.01-1.75) 0.045 |
| rs2899662 * rs324396 | 0.72 (0.55-0.93) 0.0135 | 0.61 (0.41-0.92) 0.0166 | 0.82 (0.61-1.1) 0.1836 |
| rs8042149 * rs714588 | 1.27 (1.01-1.59) 0.041 | 1.02 (0.72-1.45) 0.9143 | 1.58 (1.2-2.09) 0.0012 |
| rs4775301 * rs714588 | 1.29 (1.03-1.61) 0.025 | 1.14 (0.8-1.63) 0.4583 | 1.39 (1.05-1.84) 0.020 |
| rs4775301 * rs324396 | 0.73 (0.57-0.93) 0.0116 | 0.7 (0.48-1.02) <i>0.0605</i> | 0.9 (0.67-1.2) 0.4701 |
| rs12591848 ^b * rs2530547 ^c | 0.54 (0.36-0.8) 0.0025 | 0.81 (0.42-1.55) 0.5228 | 0.71 (0.48-1.06) <i>0.092</i> |
| rs12591848 ^b * rs963218 | 0.51 (0.35-0.74) 4.60e-04 | 0.65 (0.36-1.18) 0.1603 | 0.71 (0.47-1.06) <i>0.090</i> |
| rs4775289 * rs963218 | 1.26 (1.01-1.58) 0.0428 | 1.09 (0.78-1.52) 0.6272 | 1.3 (0.99-1.71) <i>0.058</i> |
| rs11071561 * rs727162 | 1.33 (1-1.76) 0.0471 | 1.52 (0.99-2.33) <i>0.0557</i> | 1.02 (0.73-1.43) 0.8856 |
| rs7171681 * rs963218 | 1.39 (1.09-1.77) 0.0085 | 1.01 (0.69-1.47) 0.9544 | 1.28 (0.98-1.69) <i>0.075</i> |

8

9 Odds ratios, 95% confidence intervals and *p*-values are reported for all datasets. *P*-values of
10 significant interactions are in bold letters and the background is marked green; borderline
11 significant interactions are marked in olive green and *p*-values are in italic. ^a The interaction is
12 shown in the following format: *RORA*-SNP * *NPSRI*-SNP. ^b rs12591848 was replaced by
13 rs746241 in BAMSE (SNPs are reported to be in perfect LD). ^c This interaction was
14 significant in the recent paper by Acevedo et al ²³ using BAMSE and PARSIFAL populations.
15 Looking only at the BAMSE cohort the interaction is less powerful and therefore, does not
16 reach statistical significance.

17

18 **Table 2. Replication of interaction effects between *RORA* and *NPSRI* on nocturnal**
 19 **asthma symptoms.**

| Interaction^a | NAS^b (MAGICS/ISAAC) | NAS^b (MAAS) | NBD^b (BAMSE) |
|------------------------------------|------------------------------------------|----------------------------------|-----------------------------------|
| rs1379928 * rs4775292 | 1.68 (1.08-2.6) 0.02 | 2.11 (1.16-3.84) 0.0143 | 1.23 (0.76-1.97) 0.3974 |
| rs1379928 * rs12437690 | 0.62 (0.39-0.97) 0.036 | 0.53 (0.3-0.93) 0.0254 | 0.86 (0.54-1.37) 0.5355 |
| rs1379928 * rs17204454 | 1.59 (1.04-2.43) 0.0318 | 1.99 (1.14-3.46) 0.0149 | 1.11 (0.71-1.75) 0.644 |
| rs324384 * rs2899662 | 0.65 (0.44-0.96) 0.0317 | 0.6 (0.36-0.98) 0.0395 | 0.97 (0.67-1.41) 0.8682 |
| rs324957 * rs2899662 | 0.65 (0.44-0.96) 0.032 | 0.56 (0.34-0.91) 0.02 | na |
| rs324396 * rs2899662 | 0.61 (0.4-0.95) 0.0277 | 0.48 (0.28-0.82) 0.0069 | 0.73 (0.49-1.1) 0.1309 |
| rs324396 * rs7171681 | 0.45 (0.28-0.73) 0.0013 | 0.54 (0.3-0.99) 0.0459 | 0.82 (0.54-1.24) 0.3384 |
| rs324396 * rs341382 | 0.52 (0.32-0.85) 0.0094 | 0.58 (0.31-1.07) <i>0.0825</i> | 0.9 (0.58-1.4) 0.649 |
| rs324396 * rs4775301 | 0.65 (0.44-0.96) 0.0307 | 0.63 (0.38-1.03) <i>0.065</i> | 0.87 (0.6-1.28) 0.4886 |
| rs2609234 * rs341382 | 1.74 (1.03-2.93) 0.0376 | 1.88 (0.96-3.7) <i>0.0675</i> | na |
| rs963218 * rs12591848 ^c | 0.46 (0.25-0.84) 0.0108 | 0.77 (0.37-1.6) 0.4834 | 0.6 (0.35-1.05) <i>0.0759</i> |
| rs324981 * rs11071561 | 1.51 (1.07-2.13) 0.02 | 1.57 (0.99-2.5) <i>0.0577</i> | na |
| rs740347 * rs4775289 | 1.67 (1.02-2.73) 0.041 | 1.03 (0.56-1.92) 0.9164 | 1.65 (0.97-2.8) <i>0.0646</i> |

20

21 ^a The interaction is shown in the following format: *NPSRI*-SNP * *RORA*-SNP. ^b NAS =
 22 nocturnal asthma symptoms; NBD = nocturnal breathing difficulties. ^c rs12591848 was
 23 replaced by rs746241 in BAMSE (SNPs are reported to be in perfect LD). Odds ratios, 95%
 24 confidence intervals and *p*-values are reported for all datasets, *p*-values of significant
 25 interactions are in bold letters and green background, borderline significant *p*-values are
 26 marked in italic and cells are shaded olive green. na = interaction could not be calculated as at
 27 least one of the SNPs was not available in the BAMSE cohort.

28

Table 3A. Functional relevance of selected top hits in *NPSR1* interacting to be associated with nocturnal asthma symptoms.

| SNP | Gene | N IA | N IA replicated | Location | Predicted promoter region? | SNP conserved | eQTL | TFBS |
|-----------|--------------|------|-----------------|--------------------------------------------|----------------------------|---------------|------------------------------------------------------------------------------------------|---------------------------------------------|
| rs1379928 | <i>NPSR1</i> | 9 | 3 | Intron | BRN (LD 0.88) | LD (0.99) | gene expression change of <i>ABCA7</i> , <i>GNB2L1</i> , <i>SLC4A2</i> in PBMC (LD 0.92) | CFOS, STAT3, P300 (LD 0.81) |
| rs324396 | <i>NPSR1</i> | 5 | 2 (4) | Intron <i>NPSR1</i> / exon <i>NCAPD2P1</i> | LNG, CRVX, LIV (LD 0.98) | -- | -- | 26 proteins, e.g. GATA3 and STAT3 (LD 0.98) |
| rs6972158 | <i>NPSR1</i> | 10 | 0 | Missense / Splicing site | -- | yes | eQTL of <i>NPSR1</i> in Testis (LD 0.8) | -- |
| rs1419779 | <i>NPSR1</i> | 9 | 0 | Intron | GI, PANC, LIV (LD 0.99) | -- | gene expression change of <i>DPY19L1</i> in blood | MAFF, MAFK (LD 0.99) |

Table 3B. Functional relevance of selected top hits in *RORA* interacting to be associated with nocturnal asthma symptoms.

| SNP | Gene | N IA | N IA replicated | Location | Predicted promoter region? | SNP conserved | eQTL | TFBS |
|-----------|-------------|------|-----------------|----------|----------------------------|---------------|-------------------------------------------------------------------|-----------------|
| rs2899662 | <i>RORA</i> | 5 | 3 | Intron | BLD, MUS (LD 0.95) | -- | differential exon level expression of <i>RORA</i> in brain cortex | USF1 (LD 0.85) |
| rs7171681 | <i>RORA</i> | 11 | 1 | Intron | BLD | LD (0.97) | -- | STAT3 (LD 0.98) |
| rs4775301 | <i>RORA</i> | 8 | 0 (1) | Intron | BLD (LD 0.82) | -- | <i>CTCF</i> , <i>NRSF</i> (LD 0.82) | -- |
| rs8042149 | <i>RORA</i> | 8 | 0 | Intron | -- | -- | -- | -- |
| rs4775289 | <i>RORA</i> | 7 | 0 (1) | Intron | -- | -- | -- | -- |
| rs341382 | <i>RORA</i> | 6 | 0 (2) | Intron | ESC, BLD (LD 0.95) | -- | <i>STAT3</i> (LD 0.97) | -- |

Information was obtained from several databases as indicated in the methods section. All SNPs interacting with at least 25% of the other gene's SNPs in the discovery cohort or with at least two significant replications were included (N=10). If a SNP in LD was associated with a functional change, 'LD' and the respective r^2 value is put in brackets. The count of replicated interactions includes the replications with a $p < 0.05$ and the replications with borderline significance ($p < 0.10$) in brackets. Predicted promoter region is reported if the SNP was predicted to be located in a promoter region in a selected tissue. For an exact explanation of the columns please refer to the methods section. Part A includes SNPs from *NPSRI* and Part B includes SNPs from *RORA*.

Abbreviations: N – number, IA – Interaction, eQTL – expression quantitative trait loci, TFBS – Transcription Factor Binding Site, LD – Linkage Disequilibrium, LIV – Liver, BRN – Brain, LNG – Lung, CRVX – Cervix, GI – Gastrointestinal Tract, PANC – Pancreas, BLD – Blood, MUS – Muscle, PBMC – peripheral blood monocytes.




Figure 1. Schematic depiction of the cohorts and patients involved. Excluded patients and the reason for exclusion from analyses are written on white background. Grey background indicates included patients. All non-asthmatics served as controls when evaluating the effect of the two genes on asthma and only non-asthmatics without nocturnal symptoms served as controls when the nocturnal phenotypes were the outcome. Thus, patients without information on their nocturnal asthma status were excluded for stratified analyses on the impact of nocturnal symptoms.

166x65mm (300 x 300 DPI)




Figure 2. Heat map of the interaction results of RORA*NPSRI on asthma in MAGIC/ISAAC. Color explanation to the right. Darker colors indicate stronger associations. SNPs obtained from the regular GWAS dataset are highlighted in dark grey, imputed SNPs are highlighted in light grey.

161x88mm (300 x 300 DPI)




Figure 3. Heat map of the interaction results of RORA*NPSR1 on asthma with and asthma without nocturnal symptoms in MAGIC/ISAAC. Color coding is explained on the right. Green colors indicate a significant interaction when asthma with nocturnal symptoms was the outcome whereas orange and red colors indicate a significant interaction when asthma without nocturnal symptoms was the outcome. Cells in yellow mark interactions which are significantly associated with both outcomes. Darker colors indicate a stronger association. SNPs obtained from the regular GWAS dataset are highlighted in dark grey, imputed SNPs are highlighted in light grey.

190x85mm (300 x 300 DPI)

25 which are significantly associated with both outcomes. Darker colors indicate a stronger
26 association. SNPs obtained from the regular GWAS dataset are highlighted in dark grey,
27 imputed SNPs are highlighted in light grey.

28

29

30

1 **Nocturnal asthma is affected by genetic interactions between**

2 ***RORA* and *NPSRI***

3
4 Vincent D. Gaertner¹, Sven Michel¹, John A. Curtin², Ville Pulkkinen³, Nathalie Acevedo^{4,5},
5 Cilla Söderhäll^{6,7}, Andrea von Berg⁸, Albrecht Bufe⁹, Otto Laub¹⁰, Ernst Rietschel¹¹, Andrea
6 Heinzmann¹², Burkard Simma¹³, Christian Vogelberg¹⁴, Göran Pershagen¹⁵, Erik Melén^{5,15},
7 Angela Simpson², Adnan Custovic¹⁶, Juha Kere^{6,17}, and Michael Kabesch^{1*}

8 9 **ONLINE SUPPLEMENT**

10 11 **Participant flow**

12 In MAGICS/ISAAC, we excluded 8 subjects with no asthma diagnosis and 14 subjects with
13 reported nocturnal symptoms but no diagnosed asthma, thus leaving 1,432 subjects for analysis.

14 In BAMSE, 80 subjects without information on asthma diagnosis and 307 subjects with
15 reported nocturnal symptoms but no diagnosed asthma were excluded, thus leaving 1,646

16 subjects for analyses. In MAAS, children with only one or two of the three features used to
17 differentiate asthmatics and controls were excluded from further analyses, leaving 723 children

18 in this study. For a more detailed description of all cohorts, please see Figure 1 and
19 Supplementary Table S1.

20 21 **SNP selection**

22 Since both genes under review are relatively large, SNPs were selected for analysis according
23 to a stringent and conservative approach. Firstly, we included all SNPs from both genes that
24 had been selected in a recent study on the interaction of *RORA* and *NPSRI*¹. Based on a
25 stringent literature search we then added SNPs that had been reported to be associated with
26 asthma but were not covered by the aforementioned study (the search was performed on April
27 28th 2018 and the search terms were “asthma[Title] AND GPRA [All Fields] AND
28 polymorphism [All Fields]” and “asthma[Title] AND NPSR1 [All Fields] AND polymorphism
29 [All Fields]” and “asthma[Title] AND RORA [All Fields] AND polymorphism [All Fields]”).
30 SNPs included in the analyses were obtained from the following studies:²⁻¹¹. The SNP selection
31 is depicted in Supplementary Figure S1. In total, 59 SNPs were selected. Of these, 22 SNPs had
32 been originally genotyped in our GWAS dataset¹². We then selected SNPs in perfect LD ($r^2=1$)
33 with one of the SNPs under consideration (N=4; based on a search in SnapProxy with
34 1000Genomes data as reference panel). For the remaining 33 SNPs we used imputation data on
35 the basis of the 1000Genomes dataset as described below.

36

37 **Genotyping and imputation**

38 Genotyping was performed by using the Illumina Sentrix HumanHap300 BeadChip for
39 MAGIC/ISAAC (imputation data was used when no original genotyping information was
40 available)^{12,13}. The iPLEX chemistry and the SEQUENOM platform at the Mutation Analysis
41 Facility at Karolinska Institutet (BAMSE) and the Illumina 610 quad and subsequent
42 imputation with the 1000 Genomes Phase 3 reference genome (MAAS) were used for the
43 replication cohorts.

44

45

47 **SUPPORTING FILES**

48

49 **Supplementary Figure S1. Schematic depiction of the SNP selection process.** SNPs marked
50 with an asterisk either showed no association with asthma or were already included in the
51 publication by Acevedo et al.

52

53 **Supplementary Figure S2. Heat map of the interaction results of *RORA***NPSR1* on**
54 **asthma with nocturnal symptoms and on asthma severity in MAGIC/ISAAC.** Color
55 coding is explained on the right. Green colors indicate a significant interaction when asthma
56 with nocturnal symptoms was the outcome whereas blue colors indicate a significant interaction
57 when severe asthma was the outcome. Cells in turquoise mark interactions which significantly
58 influenced both outcomes. Darker colors indicate a stronger association. SNPs obtained from
59 the regular GWAS dataset are highlighted in dark grey, imputed SNPs are highlighted in light
60 grey.

61

62 **Supplementary Figure S3. Linkage disequilibrium (LD) plot from the selected region**
63 **from *NPSR1* within MAGIC/ISAAC.** R²-values are depicted and darker shades indicate a
64 higher LD. The localization of all analyzed SNPs is depicted above the LD structure. Exons,
65 introns, and the 5' untranslated region (UTR) are highlighted.

66

67 **Supplementary Figure S4. Linkage disequilibrium (LD) plot from the selected region**
68 **from *RORA* within MAGIC/ISAAC.** R²-values are depicted and darker shades indicate a
69 higher LD. The localization of all analyzed SNPs is depicted above the LD structure. Exons,
70 introns, and the 5' untranslated region (UTR) are highlighted.

71

72 **Supplementary Figure S5. SNP selection for the functional database search.**

73 * = with at least three SNPs from the respective other gene; # = one of these SNPs is already
74 included in the other selection (thus, the overall number of selected SNPs is 10).

75

76

77 **Supplementary Table S1. Descriptive characterization of the study populations.** The

78 characteristics of the regular dataset and the imputation dataset of the MAGIC/ISAAC

79 cohort as well as the BAMSE and MAAS cohorts with all genotyped individuals included in

80 the analysis are depicted for comparison. For MAAS, age is depicted for the visit closest to 11

81 years which was mainly used in this manuscript. Different definitions of the two phenotypes

82 over the cohorts are discussed in the main text. *n = number affected/ number with data

83 available. † BAMSE is a cohort study and all samples were collected when the individuals

84 reached age 8 years. Abbreviations: SD - standard deviation.

85

86 **Supplementary Table S2. Interaction results of *RORA* * *NPSRI*-SNPs on asthma in**

87 **MAGIC/ISAAC.** Interaction results of *RORA* by *NPSRI* on asthma within

88 MAGIC/ISAAC are depicted. Originally genotyped SNPs are marked in dark grey whereas

89 imputed SNPs are marked in light grey. Odds ratios, 95 % confidence intervals and *p*-values

90 are reported for both publications. Each cell contains the results of the respective interaction

91 in the format "OR (95% CI) *p*-value". *p*-values of significant interactions are marked in bold

92 letters.

93

94 **Supplementary Table S3. Complete replication results of *RORA***NPSRI* interactions on**
95 **asthma in BAMSE and MAAS.** All SNPs with at least 3 significant interactions in the
96 original cohort and their respective replication results in BAMSE and MAAS are shown.
97 Interactions between *RORA* and *NPSRI* with the same effect direction in the replication
98 dataset as in MAGICS/ISAAC are marked in shades of green, opposing effect directions are
99 marked in shades of red. The darker the color the stronger the association. Odds ratios with
100 95% confidence intervals and *p*-values are depicted. Each cell contains the results of the
101 respective interaction in the format "OR (95% CI) *p*-value".

102

103 **Supplementary Table S4. Direct association of SNPs in *RORA* and *NPSRI* with**
104 **nocturnal asthma symptoms in MAGICS/ISAAC.** Results for logistic regression of 59
105 SNPs on nocturnal asthma symptoms with age and sex as covariates. Non-asthmatic subjects
106 with nocturnal symptoms were excluded for both analyses. Odds Ratios, 95% confidence
107 intervals and *p*-values are reported for each SNP. Significant *p*-values are indicated in bold.
108 Abbreviations: Chr – Chromosome; Position – chromosomal position; SNP – single
109 nucleotide polymorphism; MAF – minor allele frequency; OR – odds ratio; CI – confidence
110 interval; Chip – Illumina BeadChip genotyping; MALDI - MALDI-TOF-MS genotyping.

111

112 **Supplementary Table S5. Interaction results of *RORA* * *NPSRI*-SNPs on asthma with**
113 **nocturnal symptoms in MAGICS/ISAAC.** Interaction results of *RORA* by *NPSRI* after
114 stratification. Subjects with asthma as well as nocturnal symptoms (N=164 in the imputation
115 dataset; N=192 in the regular dataset) were compared with non-asthmatics (N=630 in the
116 imputation dataset; N=660 in the regular dataset) within MAGICS/ISAAC. SNPs from *RORA*
117 are on the vertical axis while SNPs from *NPSRI* are depicted horizontally. Originally

118 genotyped SNPs are marked in dark grey whereas imputed SNPs are marked in light grey.
119 Odds ratios, 95 % confidence intervals and *p*-values reported for both publications. Each cell
120 contains the results of the respective interaction in the format "OR (95% CI) *p*-value". *p*-
121 values of significant interactions are marked in bold letters.

122

123 **Supplementary Table S6. Complete replication results of *RORA***NPSRI* interactions on**
124 **nocturnal asthma in BAMSE and MAAS.** All SNPs with at least 3 significant interactions
125 in the original cohort and their respective replication results in BAMSE and MAAS are
126 shown. Interactions between *RORA* and *NPSRI* with the same effect direction in the
127 replication dataset as in MAGIC/ISAAC are marked in shades of green, opposing effect
128 directions are marked in shades of red. The darker the color the stronger the association. Odds
129 ratios with 95% confidence intervals and *p*-values are shown. Results of the respective
130 interactions are depicted in the format "OR (95% CI) *p*-value".

131

132 **Supplementary Table S7. Validation of *RORA***NPSRI* interaction results on nocturnal**
133 **asthma in MAAS at age 16.** Interaction effects of *RORA* and *NPSRI* on nocturnal asthma at
134 age 16 for all interactions with at least borderline significant effects on nocturnal asthma at age
135 11 are shown. Interactions between *RORA* and *NPSRI* with the same effect direction at age 16
136 as at age 11 are marked in shades of green, opposing effect directions are marked in shades of
137 red. The darker the color the stronger the association. Odds ratios with 95% confidence intervals
138 and *p*-values are shown. Results of the respective interaction are depicted in the format "OR
139 (95% CI) *p*-value".

140

141 **Supplementary Table S8. Interaction results of *RORA* * *NPSRI*-SNPs on asthma**
142 **without nocturnal symptoms in MAGIC/ISAAC.** Interaction results of *RORA* by *NPSRI*
143 after stratification. Subjects with asthma but without nocturnal symptoms (N=228 in the
144 imputation dataset; N=268 in the regular dataset) were compared with non-asthmatics (N=630
145 in the imputation dataset; N=660 in the regular dataset) in MAGIC/ISAAC. SNPs from
146 *RORA* are on the vertical axis while SNPs from *NPSRI* are depicted horizontally. Originally
147 genotyped SNPs are marked in dark grey whereas imputed SNPs are marked in light grey.
148 Odds ratios, 95 % confidence intervals and *p*-values reported for both publications. Each cell
149 contains the results of the respective interaction in the format "OR (95% CI) *p*-value". *p*-
150 values of significant interactions are marked in bold letters.

151
152 **Supplementary Table S9. Complete replication results of *RORA***NPSRI* interactions on**
153 **asthma without nocturnal symptoms in BAMSE and MAAS.** All SNPs with at least 3
154 significant interactions in the original cohort and their respective replication results in BAMSE
155 and MAAS are shown. Interactions between *RORA* and *NPSRI* with the same effect direction
156 in the replication dataset as in MAGIC/ISAAC are marked in shades of green, opposing effect
157 directions are marked in shades of red. The darker the color the stronger the association. Odds
158 ratios with 95% confidence intervals and *p*-values are shown. Results of the respective
159 interactions are depicted in the format "OR (95% CI) *p*-value".

160
161 **Supplementary Table S10. Interaction results of *RORA* * *NPSRI*-SNPs on severe asthma**
162 **in MAGIC/ISAAC.** Interaction results of *RORA* by *NPSRI* on asthma severity. SNPs from
163 *RORA* are on the vertical axis while SNPs from *NPSRI* are depicted horizontally. Originally
164 genotyped SNPs are marked in dark grey whereas imputed SNPs are marked in light grey.

165 Odds ratios, 95 % confidence intervals and p -values reported for both publications. Each cell
166 contains the results of the respective interaction in the format "OR (95% CI) p -value". p -
167 values of significant interactions are marked in bold letters.

168

169 **Supplementary Table S11. Complete replication results of interaction effects between**
170 **RORA and NPSR1 on asthma severity.** All SNPs with at least 3 significant interactions in
171 the original cohort and their respective replication results in BAMSE and MAAS are shown.
172 Interactions between *RORA* and *NPSR1* with the same effect direction in the replication
173 dataset as in MAGICS/ISAAC are marked in shades of green, opposing effect directions are
174 marked in shades of red. The darker the color the stronger the association. Estimates, standard
175 errors and p -values are reported for all datasets, p -values of significant interactions are in bold
176 letters. na = interaction could not be calculated as at least one of the SNPs was not available
177 in the BAMSE cohort.

178

179

180

181

182 **REFERENCES**

- 183 1. Acevedo N, Sääf A, Söderhäll C, Melén E, Mandelin J, Pietras CO, Ezer S, Karisola P,
184 Vendelin J, Gennäs GB af, et al. Interaction between retinoid acid receptor-related orphan
185 receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma. *PloS one*.
186 2013;8(4):e60111. doi:10.1371/journal.pone.0060111
- 187 2. Melén E, Bruce S, Doekes G, Kabesch M, Laitinen T, Lauener R, Lindgren CM, Riedler J,
188 Scheynius A, van Hage-Hamsten M, et al. Haplotypes of G Protein–coupled Receptor 154
189 Are Associated with Childhood Allergy and Asthma. *American Journal of Respiratory and*
190 *Critical Care Medicine*. 2005;171(10):1089–1095. doi:10.1164/rccm.200410-1317OC
- 191 3. Kormann MSD, Carr D, Klopp N, Illig T, Leupold W, Fritzsch C, Weiland SK, von Mutius
192 E, Kabesch M. G-Protein-coupled receptor polymorphisms are associated with asthma in a
193 large German population. *American journal of respiratory and critical care medicine*.
194 2005;171(12):1358–62. doi:10.1164/rccm.200410-1312OC
- 195 4. Castro-Giner F, de Cid R, Gonzalez JR, Jarvis D, Heinrich J, Janson C, Omenaas ER,
196 Matheson MC, Pin I, Antó JM, et al. Positionally cloned genes and age-specific effects in
197 asthma and atopy: an international population-based cohort study (ECRHS). *Thorax*.
198 2010;65(2):124–31. doi:10.1136/thx.2009.119628
- 199 5. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E,
200 Farrall M, Lathrop M, Cookson WOCM, et al. A large-scale, consortium-based genomewide
201 association study of asthma. *The New England journal of medicine*. 2010;363(13):1211–21.
202 doi:10.1056/NEJMoa0906312
- 203 6. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, Himes
204 BE, Levin AM, Mathias RA, Hancock DB, et al. Meta-analysis of genome-wide association
205 studies of asthma in ethnically diverse North American populations. *Nature genetics*.

- 206 2011;43(9):887–92.
- 207 7. Hersh CP, Raby BA, Soto-Quirós ME, Murphy AJ, Avila L, Lasky-Su J, Sylvia JS,
208 Klanderman BJ, Lange C, Weiss ST, et al. Comprehensive testing of positionally cloned
209 asthma genes in two populations. *American journal of respiratory and critical care medicine*.
210 2007;176(9):849–57. doi:10.1164/rccm.200704-592OC
- 211 8. Blakey JD, Sayers I, Ring SM, Strachan DP, Hall IP. Positionally cloned asthma
212 susceptibility gene polymorphisms and disease risk in the British 1958 Birth Cohort. *Thorax*.
213 2009;64(5):381–7. doi:10.1136/thx.2008.102053
- 214 9. Ramasamy A, Kuokkanen M, Vedantam S, Gajdos ZK, Couto Alves A, Lyon HN, Ferreira
215 MAR, Strachan DP, Zhao JH, Abramson MJ, et al. Genome-wide association studies of
216 asthma in population-based cohorts confirm known and suggested loci and identify an
217 additional association near HLA. *PloS one*. 2012;7(9):e44008.
218 doi:10.1371/journal.pone.0044008
- 219 10. Vergara C, Jiménez S, Acevedo N, Martínez B, Mercado D, Gusmão L, Rafaels N, Hand
220 T, Barnes KC, Caraballo L. Association of G-protein-coupled receptor 154 with asthma and
221 total IgE in a population of the Caribbean coast of Colombia. *Clinical and experimental*
222 *allergy : journal of the British Society for Allergy and Clinical Immunology*.
223 2009;39(10):1558–68. doi:10.1111/j.1365-2222.2009.03311.x
- 224 11. Daley D, Lemire M, Akhabir L, Chan-Yeung M, He JQ, McDonald T, Sandford A,
225 Stefanowicz D, Tripp B, Zamar D, et al. Analyses of associations with asthma in four asthma
226 population samples from Canada and Australia. *Human genetics*. 2009;125(4):445–59.
227 doi:10.1007/s00439-009-0643-8
- 228 12. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg
229 A, Bufe A, Rietschel E, et al. Genetic variants regulating ORMDL3 expression contribute to

230 the risk of childhood asthma. *Nature*. 2007;448(7152):470–3. doi:10.1038/nature06014

231 13. Michel S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, Schedel M, Vogelberg C,
232 von Mutius E, von Berg A, et al. Unifying candidate gene and GWAS Approaches in Asthma.
233 *PloS one*. 2010;5(11):e13894. doi:10.1371/journal.pone.0013894

234

Supplementary Table S1. Descriptive characterization of the study populations.

| Parameter | MAGICS/ISAAC | MAGICS/ISAAC imputation dataset | MAAS | BAMSE |
|-----------------------------------------------------------------------|-----------------|---------------------------------------|----------------|---------------------|
| Male sex, n* (%) | 838/1432 (58.5) | 746/1289 (57.9) | 382/723 (52.8) | 1051/2033 (51.7) |
| Age (years), mean (SD) | 10.3 (2.2) | 10.3 (2.1) | 11.5 (0.5) | 8 [†] |
| Asthmatics, n* (%) | 763/1432 (53.3) | 651/1289 (50.5) | 177/723 (24.5) | 292/1646 (17.7) |
| Nocturnal asthmatics / nocturnal breathing difficulties, n* (%) | 192/1120 (17.1) | 164/1022 (16.1) | 89/635 (14.0) | 142/1646 (8.6) |

Supplementary Table S3. Complete replication results of RORA*NPSR1 interactions on asthma in BAMSE and MAAS.

| |
|--------------------------------------------------|
| effect direction different to MAGIC/ISAAC |
| effect direction the same as in MAGIC/ISAAC |
| borderline significant replication |
| significant replication of interaction on asthma |

| RORA | NPSR1 | Asthma (MAGIC/ISAAC) | Asthma (BAMSE) | Asthma (MAAS) |
|------------|-----------|----------------------------------|--------------------------------|--------------------------------|
| rs7173227 | rs2530547 | 0.7 (0.5-0.99) 0.0446 | 0.75 (0.54-1.05) 0.0934 | 1.07 (0.62-1.84) 0.8036 |
| | rs887020 | 0.71 (0.51-0.98) 0.0397 | 0.9 (0.64-1.27) 0.5487 | 0.83 (0.5-1.37) 0.4622 |
| | rs963218 | 0.66 (0.48-0.91) 0.0115 | 0.74 (0.53-1.04) 0.0814 | 1.05 (0.66-1.66) 0.8478 |
| rs2899662 | rs887020 | 1.34 (1.06-1.7) 0.0149 | 1.41 (1.06-1.87) 0.0182 | 1.46 (1.02-2.09) 0.0407 |
| | rs963218 | 1.39 (1.1-1.75) 0.0058 | 1.33 (1.01-1.75) 0.0448 | 1.29 (0.9-1.83) 0.162 |
| | rs324396 | 0.72 (0.55-0.93) 0.0135 | 0.82 (0.61-1.1) 0.1836 | 0.61 (0.41-0.92) 0.0166 |
| | rs324957 | 0.79 (0.62-0.99) 0.0446 | na | 0.9 (0.63-1.28) 0.5538 |
| | rs740347 | 1.45 (1.06-1.99) 0.0204 | 1.23 (0.84-1.81) 0.2787 | 0.97 (0.59-1.6) 0.9012 |
| | rs1419779 | 1.35 (1.05-1.72) 0.0173 | na | 1.08 (0.75-1.56) 0.6741 |
| rs10162630 | rs1345267 | 0.7 (0.56-0.88) 0.0024 | na | 0.85 (0.6-1.21) 0.3677 |
| | rs323922 | 0.77 (0.61-0.97) 0.0241 | 0.88 (0.68-1.15) 0.3564 | 0.8 (0.57-1.12) 0.1864 |
| | rs324396 | 1.29 (1-1.66) 0.0486 | 1.16 (0.88-1.55) 0.2963 | 1.35 (0.93-1.97) 0.1131 |
| rs12591848 | rs2609234 | 0.58 (0.34-0.99) 0.0458 | na | 1.87 (0.9-3.87) 0.0922 |
| | rs714588 | 0.63 (0.43-0.92) 0.0178 | 0.65 (0.43-0.98) 0.0412 | 1.26 (0.69-2.32) 0.4492 |
| | rs2530547 | 0.54 (0.36-0.8) 0.0025 | 0.71 (0.48-1.06) 0.0915 | 0.81 (0.42-1.55) 0.5228 |
| | rs887020 | 0.54 (0.36-0.8) 0.0019 | 0.82 (0.55-1.23) 0.3374 | 0.75 (0.4-1.43) 0.3883 |
| | rs1379928 | 0.64 (0.41-0.99) 0.0442 | 0.87 (0.52-1.45) 0.5946 | 1.29 (0.64-2.58) 0.4725 |
| | rs963218 | 0.51 (0.35-0.74) 4.60e-04 | 0.71 (0.47-1.06) 0.0897 | 0.65 (0.36-1.18) 0.1603 |
| | rs1345267 | 1.69 (1.15-2.5) 0.0079 | na | 1.08 (0.64-1.83) 0.7668 |
| | rs1419779 | 0.45 (0.3-0.68) 1.51e-04 | na | 0.77 (0.43-1.36) 0.3633 |
| rs8042149 | rs714588 | 1.27 (1.01-1.59) 0.0407 | 1.58 (1.2-2.09) 0.0012 | 1.02 (0.72-1.45) 0.9143 |
| | rs1379928 | 1.38 (1.07-1.8) 0.0143 | 1.15 (0.82-1.61) 0.4214 | 0.85 (0.58-1.25) 0.4141 |
| | rs963218 | 1.32 (1.05-1.67) 0.0194 | 1 (0.77-1.3) 0.9809 | 1.05 (0.75-1.47) 0.7783 |
| | rs323922 | 1.27 (1.02-1.6) 0.0342 | 0.97 (0.75-1.27) 0.8368 | 0.99 (0.71-1.39) 0.9738 |
| | rs324396 | 0.75 (0.59-0.96) 0.0226 | 0.9 (0.68-1.2) 0.4705 | 0.8 (0.55-1.15) 0.2267 |
| rs4775301 | rs714588 | 1.29 (1.03-1.61) 0.0248 | 1.39 (1.05-1.84) 0.0202 | 1.14 (0.8-1.63) 0.4583 |
| | rs1379928 | 1.34 (1.03-1.74) 0.0276 | 1.02 (0.73-1.44) 0.9001 | 0.84 (0.56-1.25) 0.3898 |
| | rs963218 | 1.36 (1.08-1.71) 0.0097 | 1.01 (0.77-1.33) 0.9379 | 1.05 (0.74-1.49) 0.7731 |
| | rs324396 | 0.73 (0.57-0.93) 0.0116 | 0.9 (0.67-1.2) 0.4701 | 0.7 (0.48-1.02) 0.0605 |
| | rs1419779 | 1.27 (1-1.61) 0.05 | na | 1.01 (0.71-1.45) 0.9444 |
| rs11071561 | rs963218 | 1.29 (1.02-1.64) 0.0337 | 1.13 (0.87-1.47) 0.3656 | 1.32 (0.91-1.9) 0.1392 |
| | rs324396 | 0.77 (0.6-0.99) 0.041 | 1.07 (0.8-1.43) 0.6608 | 0.62 (0.42-0.93) 0.0191 |

| | | | | |
|------------|-----------|--------------------------------|-------------------------|-------------------------|
| | rs727162 | 1.33 (1-1.76) 0.0471 | 1.02 (0.73-1.43) 0.8856 | 1.52 (0.99-2.33) 0.0557 |
| rs8043356 | rs1379928 | 0.67 (0.45-1) 0.0484 | 1.01 (0.64-1.6) 0.9664 | 0.92 (0.53-1.59) 0.7578 |
| rs4775289 | | 1.26 (1.01-1.58) 0.0428 | 1.3 (0.99-1.71) 0.058 | 1.09 (0.78-1.52) 0.6272 |
| rs7171681 | | 1.39 (1.09-1.77) 0.0085 | 1.28 (0.98-1.69) 0.0752 | 1.01 (0.69-1.47) 0.9544 |
| rs7169281 | rs963218 | 0.79 (0.63-0.99) 0.0374 | 0.91 (0.7-1.17) 0.461 | 1.3 (0.91-1.85) 0.156 |
| rs341382 | | 1.29 (1-1.66) 0.0494 | 1.26 (0.95-1.67) 0.1072 | 1.19 (0.81-1.76) 0.373 |
| rs6494229 | | 1.29 (1.03-1.62) 0.0263 | 1.12 (0.87-1.46) 0.3811 | 1.32 (0.91-1.92) 0.1373 |
| rs17204395 | | 2.36 (1.17-4.74) 0.0159 | | 0.99 (0.4-2.46) 0.9761 |
| rs7164773 | rs323917 | 0.61 (0.38-1) 0.048 | 0.72 (0.4-1.31) 0.2786 | 0.87 (0.39-1.91) 0.7251 |
| rs12438866 | | 1.72 (1.03-2.87) 0.0372 | 1.02 (0.57-1.8) 0.9512 | 1.35 (0.65-2.82) 0.4265 |
| rs17204454 | | 0.56 (0.34-0.92) 0.0228 | 1.43 (0.81-2.53) 0.223 | 1.02 (0.48-2.18) 0.9512 |
| rs11635314 | | 1.43 (1.01-2.04) 0.0461 | na | 1.3 (0.83-2.04) 0.2486 |
| rs17204395 | rs1345267 | 0.73 (0.55-0.99) 0.04 | na | 0.73 (0.46-1.17) 0.1905 |
| rs341459 | | 0.77 (0.61-0.98) 0.0373 | na | 0.72 (0.48-1.07) 0.1007 |
| rs4775289 | rs1419779 | 1.27 (1-1.61) 0.0462 | na | 1.05 (0.74-1.49) 0.7823 |
| rs922782 | | 1.28 (1.01-1.63) 0.0384 | na | 0.87 (0.61-1.24) 0.436 |

Supplementary Table S4. Direct association of SNPs in *RORA* and *NPSR1* with nocturnal asthma symptoms in MAGIC/ISAAC

| Chr | SNP | Position | Dataset | Gene | Minor | MAF | N | Nocturnal asthma | |
|-----|------------|----------|---------|--------------|--------|------|-----|--------------------|---------------|
| | | | | | allele | | | OR (95% CI) | p-value |
| 7 | rs2609234 | 34648813 | MALDI | <i>NPSR1</i> | T | 0,16 | 727 | 0.68 (0.47 – 1.00) | 0,05 |
| 7 | rs1006392 | 34651330 | MALDI | <i>NPSR1</i> | C | 0,43 | 733 | 1.04 (0.80 – 1.34) | 0,76 |
| 7 | rs714588 | 34653614 | MALDI | <i>NPSR1</i> | G | 0,44 | 734 | 0.79 (0.61 – 1.03) | 0,076 |
| 7 | rs1963499 | 34657848 | Imputed | <i>NPSR1</i> | A | 0,1 | 794 | 0.97 (0.64 – 1.46) | 0,88 |
| 7 | rs2168890 | 34657860 | Imputed | <i>NPSR1</i> | T | 0,13 | 794 | 0.88 (0.60 – 1.30) | 0,51 |
| 7 | rs2530547 | 34658310 | MALDI | <i>NPSR1</i> | T | 0,36 | 792 | 0.98 (0.76 – 1.26) | 0,85 |
| 7 | rs887020 | 34658370 | MALDI | <i>NPSR1</i> | A | 0,44 | 836 | 0.96 (0.75 – 1.22) | 0,56 |
| 7 | rs1379928 | 34661677 | Chip | <i>NPSR1</i> | G | 0,22 | 789 | 0.77 (0.56 – 1.05) | 0,096 |
| 7 | rs963218 | 34672157 | Imputed | <i>NPSR1</i> | A | 0,45 | 794 | 0.87 (0.67 – 1.12) | 0,27 |
| 7 | rs2609215 | 34676155 | Chip | <i>NPSR1</i> | C | 0,08 | 794 | 0.73 (0.45 – 1.19) | 0,21 |
| 7 | rs323917 | 34702031 | MALDI | <i>NPSR1</i> | G | 0,07 | 735 | 0.82 (0.48 – 1.41) | 0,48 |
| 7 | rs1345267 | 34708447 | Chip | <i>NPSR1</i> | G | 0,39 | 794 | 1.21 (0.94 – 1.57) | 0,14 |
| 7 | rs323922 | 34709170 | Imputed | <i>NPSR1</i> | C | 0,42 | 794 | 1.18 (0.91 – 1.52) | 0,21 |
| 7 | rs324384 | 34742415 | Imputed | <i>NPSR1</i> | C | 0,43 | 794 | 0.88 (0.68 – 1.14) | 0,34 |
| 7 | rs324396 | 34750511 | Chip | <i>NPSR1</i> | T | 0,3 | 759 | 0.89 (0.68 – 1.18) | 0,44 |
| 7 | rs324957 | 34761760 | Chip | <i>NPSR1</i> | A | 0,43 | 793 | 0.91 (0.70 – 1.18) | 0,47 |
| 7 | rs740347 | 34772690 | MALDI | <i>NPSR1</i> | C | 0,14 | 736 | 1.08 (0.75 – 1.55) | 0,69 |
| 7 | rs1419779 | 34773696 | Chip | <i>NPSR1</i> | G | 0,34 | 794 | 0.97 (0.75 – 1.27) | 0,85 |
| 7 | rs324981 | 34778501 | Imputed | <i>NPSR1</i> | T | 0,49 | 794 | 1.13 (0.88 – 1.44) | 0,34 |
| 7 | rs325462 | 34810234 | Imputed | <i>NPSR1</i> | A | 0,47 | 794 | 0.87 (0.68 – 1.12) | 0,28 |
| 7 | rs17789420 | 34813053 | Imputed | <i>NPSR1</i> | A | 0,1 | 794 | 1.03 (0.68 – 1.55) | 0,91 |
| 7 | rs34705969 | 34827512 | Imputed | <i>NPSR1</i> | T | 0,03 | 794 | 1.85 (0.90 – 3.81) | 0,092 |
| 7 | rs727162 | 34834426 | Imputed | <i>NPSR1</i> | G | 0,21 | 794 | 1.13 (0.83 – 1.55) | 0,44 |
| 7 | rs6972158 | 34849570 | MALDI | <i>NPSR1</i> | G | 0,33 | 834 | 0.77 (0.59 – 0.99) | 0,048 |
| 15 | rs17191582 | 60722975 | Imputed | <i>RORA</i> | G | 0,16 | 794 | 1.23 (0.88 – 1.71) | 0,23 |
| 15 | rs6494221 | 60723908 | Chip | <i>RORA</i> | C | 0,2 | 793 | 1.17 (0.87 – 1.57) | 0,31 |
| 15 | rs8043356 | 60723970 | Imputed | <i>RORA</i> | T | 0,14 | 794 | 1.10 (0.76 – 1.59) | 0,63 |
| 15 | rs12899193 | 60724097 | Imputed | <i>RORA</i> | C | 0,32 | 794 | 1.14 (0.87 – 1.48) | 0,33 |
| 15 | rs12909890 | 60725778 | Imputed | <i>RORA</i> | G | 0,37 | 794 | 1.34 (1.03 – 1.74) | 0,0321 |
| 15 | rs8024629 | 60728055 | Imputed | <i>RORA</i> | A | 0,17 | 794 | 1.12 (0.82 – 1.54) | 0,46 |
| 15 | rs11635314 | 60736287 | Imputed | <i>RORA</i> | T | 0,13 | 794 | 1.06 (0.72 – 1.57) | 0,76 |
| 15 | rs4775289 | 60736677 | Chip | <i>RORA</i> | A | 0,43 | 794 | 0.94 (0.73 – 1.22) | 0,64 |
| 15 | rs17237367 | 60739770 | Imputed | <i>RORA</i> | A | 0,23 | 794 | 0.90 (0.66 – 1.23) | 0,52 |
| 15 | rs17191596 | 60743552 | Imputed | <i>RORA</i> | C | 0,12 | 794 | 1.40 (0.99 – 1.98) | 0,059 |
| 15 | rs4775292 | 60746874 | Chip | <i>RORA</i> | T | 0,39 | 794 | 0.80 (0.61 – 1.04) | 0,094 |
| 15 | rs17204367 | 60748287 | Imputed | <i>RORA</i> | G | 0,41 | 794 | 1.11 (0.86 – 1.43) | 0,42 |

| | | | | | | | | | |
|----|------------|----------|---------|------|---|------|-----|--------------------|-------|
| 15 | rs17204395 | 60757882 | Chip | RORA | T | 0,18 | 794 | 1.14 (0.83 – 1.56) | 0,4 |
| 15 | rs12437690 | 60763233 | Imputed | RORA | A | 0,4 | 794 | 1.20 (0.93 – 1.53) | 0,16 |
| 15 | rs9302215 | 60768168 | Chip | RORA | T | 0,36 | 785 | 1.12 (0.86 – 1.45) | 0,39 |
| 15 | rs17204440 | 60773888 | Imputed | RORA | A | 0,49 | 794 | 1.11 (0.86 – 1.43) | 0,44 |
| 15 | rs7164773 | 60775749 | Chip | RORA | T | 0,5 | 794 | 0.86 (0.67 – 1.10) | 0,24 |
| 15 | rs10519067 | 60776148 | Chip | RORA | A | 0,13 | 793 | 0.98 (0.67 – 1.44) | 0,92 |
| 15 | rs12438866 | 60776321 | Imputed | RORA | C | 0,38 | 794 | 1.23 (0.94 – 1.60) | 0,13 |
| 15 | rs17204454 | 60776612 | Chip | RORA | C | 0,48 | 794 | 0.81 (0.63 – 1.04) | 0,095 |
| 15 | rs922782 | 60777984 | Imputed | RORA | G | 0,49 | 794 | 0.88 (0.68 – 1.13) | 0,32 |
| 15 | rs7173227 | 60779075 | Chip | RORA | T | 0,14 | 789 | 1.15 (0.80 – 1.64) | 0,45 |
| 15 | rs2899662 | 60784020 | Imputed | RORA | T | 0,37 | 794 | 0.86 (0.66 – 1.13) | 0,28 |
| 15 | rs341459 | 60788136 | Imputed | RORA | C | 0,3 | 794 | 1.01 (0.77 – 1.33) | 0,92 |
| 15 | rs10162630 | 60792529 | Chip | RORA | T | 0,49 | 794 | 1.06 (0.82 – 1.36) | 0,68 |
| 15 | rs12591848 | 60793494 | Chip | RORA | A | 0,1 | 794 | 1.08 (0.72 – 1.62) | 0,72 |
| 15 | rs7171681 | 60819129 | Chip | RORA | C | 0,31 | 794 | 0.81 (0.61 – 1.08) | 0,15 |
| 15 | rs7169281 | 60821905 | Imputed | RORA | C | 0,49 | 794 | 1.07 (0.84 – 1.36) | 0,59 |
| 15 | rs10152719 | 60822458 | Imputed | RORA | T | 0,17 | 794 | 0.97 (0.69 – 1.36) | 0,85 |
| 15 | rs341382 | 60825632 | Imputed | RORA | C | 0,28 | 794 | 0.82 (0.61 – 1.10) | 0,18 |
| 15 | rs341392 | 60832036 | Imputed | RORA | C | 0,22 | 794 | 0.96 (0.71 – 1.29) | 0,79 |
| 15 | rs6494229 | 60832180 | Imputed | RORA | A | 0,47 | 794 | 0.93 (0.73 – 1.20) | 0,59 |
| 15 | rs8042149 | 60832754 | Imputed | RORA | T | 0,45 | 794 | 0.96 (0.75 – 1.23) | 0,74 |
| 15 | rs4775301 | 60834660 | Imputed | RORA | T | 0,46 | 794 | 0.85 (0.66 – 1.09) | 0,21 |
| 15 | rs11071561 | 60839484 | Imputed | RORA | T | 0,41 | 794 | 0.93 (0.72 – 1.21) | 0,6 |

Supplementary Table S5. Interaction results of RORA * NPSR1-SNPs on asthma with nocturnal symptoms in MAGICS/ISAAC.

| | | NPSR1 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-------------|--------------------|------------------|------------------|------------------|--------------------|------------------|------------------|--------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|-------------------|------------------|-------------------|------------------|------------------|------------------|-------------------|-------------------|-------------------|-------------------|--------|--|
| | | rs2605234 | rs1006392 | rs174588 | rs1963499 | rs2168890 | rs2325347 | rs882700 | rs1373928 | rs962318 | rs2609215 | rs323917 | rs1345267 | rs232922 | rs323484 | rs324396 | rs324957 | rs740347 | rs1419779 | rs324581 | rs323462 | rs17789420 | rs43705969 | rs727162 | rs697218 | | | | |
| rs17191582 | 0.87 (0.44-1.75) | 1.14 (0.7025) | 0.89 (0.6101) | 1.25 (0.6404) | 1.09 (0.57-0.9989) | 1.1 (0.49-2.02) | 0.9 (0.54-1.5) | 1.11 (0.69-0.9806) | 0.99 (0.5)-1.71 | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs6494221 | 0.97 (0.51-1.85) | 1.02 (0.66) | 0.91 (0.55) | 1.19 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs8043356 | 0.47 (0.2-1.12) | 0.87 (0.51-1.48) | 1.09 (0.64-1.8) | 0.94 (0.39-0.88) | 0.93 (0.37-1.38) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | 0.87 (0.51-1.48) | 1.09 (0.64-1.8) | 0.94 (0.39-0.88) | 0.93 (0.37-1.38) | 0.93 (0.37-1.38) | 0.93 (0.37-1.38) | 0.93 (0.37-1.38) | | |
| rs12899193 | 1.12 (0.68-1.9) | 0.9 (0.58-1.4) | 1.08 (0.62-1.8) | 1.19 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs12909890 | 1.48 (0.598-1.08) | 0.56 (0.2-1.1) | 0.7 (0.37-1.2) | 1.13 (0.69-1.9) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs11633314 | 1.17 (0.1109-1.92) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs4775389 | 3.32 (0.0193-1.22) | 0.61 (0.33-1.2) | 0.95 (0.57-1.6) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | |
| rs17237367 | 0.62 (0.3-1.2) | 0.81 (0.53-1.5) | 0.95 (0.57-1.6) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | |
| rs17191596 | 1.78 (0.5)-1.05 | 1.14 (0.7)-1.9 | 0.89 (0.57-1.5) | 1.25 (0.6404) | 1.09 (0.57-0.9989) | 1.1 (0.49-2.02) | 0.9 (0.54-1.5) | 1.11 (0.69-0.9806) | 0.99 (0.5)-1.71 | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs4775292 | 0.31 (0.0226-0.87) | 0.52 (0.26-0.96) | 0.63 (0.37-1.09) | 0.89 (0.36-1.4) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs172204367 | 1.44 (0.5821-0.96) | 1.18 (0.51-2.5) | 0.509 (0.19-1.4) | 1.31 (0.694) | 2.26 (0.476) | 2.16 (0.473) | 1.65 (0.5529) | 1.39 (0.8642) | 1.34 (0.6991) | 1.94 (0.9393) | 2.71 (0.4819) | 1.33 (0.7424) | 1.63 (0.9462) | 1.62 (0.9232) | 1.65 (0.9409) | 1.32 (0.7332) | 1.29 (0.5246) | 1.16 (0.4684) | 1.23 (0.2125) | 3.92 (0.6403) | 1.78 (0.5626) | 0.92 (0.4173) | 1.66 (0.62) | 1.11 (0.49) | 1.51 (0.6) | 0.91 (0.41) | 0.7 (0.59) | 0.8978 | |
| rs172204395 | 0.98 (0.48-1.9) | 1.45 (0.639-2.5) | 0.785 (0.3-1.6) | 1.06 (0.6482) | 2.08 (1.0504) | 3.3 (0.1504) | 2.3 (0.1057) | 2.38 (0.0616) | 1.59 (0.7738) | 2.29 (0.0768) | 2.47 (0.7939) | 2.21 (0.2072) | 1.05 (0.0821) | 1.26 (0.3522) | 1.70 (0.6116) | 1.19 (0.5549) | 1.72 (0.6745) | 1.64 (0.806) | 1.85 (0.4125) | 1.35 (0.5867) | 1.85 (0.3666) | 1.44 (0.3477) | 0.10 (0.01) | 2.84 (0.0674) | 1.08 (0.0974) | | | | |
| rs12437690 | 0.56 (0.34-0.95) | 1.2 (0.85-2.1) | 0.73 (0.52-1.3) | 1.03 (0.57-1.8) | 1.03 (0.61-1.8) | 1.06 (0.61-1.9) | 1.07 (0.62-1.9) | 1.06 (0.61-1.9) | 1.06 (0.61-1.9) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs93202215 | 1.54 (0.6182-2.8) | 1.81 (0.966-3.2) | 1.19 (0.713-2.0) | 2.32 (0.5366) | 2.26 (0.4405) | 1.24 (0.711) | 1.71 (0.4597) | 1.94 (0.2968) | 1.39 (0.8518) | 2.13 (0.8899) | 2.06 (0.7369) | 1.81 (0.762) | 1.28 (0.5033) | 1.37 (0.7171) | 1.84 (0.1699) | 1.6 (0.8699) | 1.79 (0.2158) | 1.44 (0.5993) | 1.27 (0.6249) | 1.21 (0.3905) | 1.71 (0.2796) | 1.94 (0.0367) | 2.06 (0.2265) | 0.89 (0.116) | 1.66 (0.59) | 1.21 (0.48) | 0.7 (0.59) | 0.8978 | |
| rs172204440 | 1.28 (0.3281-1.07) | 0.62 (0.3-1.2) | 0.95 (0.57-1.6) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | |
| rs17614773 | 1.83 (0.8175-3.0) | 1.18 (0.55-2.4) | 1.49 (0.99-2.6) | 1.31 (0.694) | 2.26 (0.476) | 2.16 (0.473) | 1.65 (0.5529) | 1.39 (0.8642) | 1.34 (0.6991) | 1.94 (0.9393) | 2.71 (0.4819) | 1.33 (0.7424) | 1.63 (0.9462) | 1.62 (0.9232) | 1.65 (0.9409) | 1.32 (0.7332) | 1.29 (0.5246) | 1.16 (0.4684) | 1.23 (0.2125) | 3.92 (0.6403) | 1.78 (0.5626) | 0.92 (0.4173) | 1.66 (0.62) | 1.11 (0.49) | 1.51 (0.6) | 0.91 (0.41) | 0.7 (0.59) | 0.8978 | |
| rs10519067 | 0.66 (0.38-1.13) | 0.78 (0.55-1.4) | 1.08 (0.6482) | 2.08 (1.0504) | 3.3 (0.1504) | 2.3 (0.1057) | 2.38 (0.0616) | 1.59 (0.7738) | 2.29 (0.0768) | 2.47 (0.7939) | 2.21 (0.2072) | 1.05 (0.0821) | 1.26 (0.3522) | 1.70 (0.6116) | 1.19 (0.5549) | 1.72 (0.6745) | 1.64 (0.806) | 1.85 (0.4125) | 1.35 (0.5867) | 1.85 (0.3666) | 1.44 (0.3477) | 0.10 (0.01) | 2.84 (0.0674) | 1.08 (0.0974) | | | | | |
| rs12438866 | 0.56 (0.34-0.95) | 1.2 (0.85-2.1) | 0.73 (0.52-1.3) | 1.03 (0.57-1.8) | 1.03 (0.61-1.8) | 1.06 (0.61-1.9) | 1.07 (0.62-1.9) | 1.06 (0.61-1.9) | 1.06 (0.61-1.9) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs172044356 | 1.54 (0.6182-2.8) | 1.81 (0.966-3.2) | 1.19 (0.713-2.0) | 2.32 (0.5366) | 2.26 (0.4405) | 1.24 (0.711) | 1.71 (0.4597) | 1.94 (0.2968) | 1.39 (0.8518) | 2.13 (0.8899) | 2.06 (0.7369) | 1.81 (0.762) | 1.28 (0.5033) | 1.37 (0.7171) | 1.84 (0.1699) | 1.6 (0.8699) | 1.79 (0.2158) | 1.44 (0.5993) | 1.27 (0.6249) | 1.21 (0.3905) | 1.71 (0.2796) | 1.94 (0.0367) | 2.06 (0.2265) | 0.89 (0.116) | 1.66 (0.59) | 1.21 (0.48) | 0.7 (0.59) | 0.8978 | |
| rs17204440 | 1.28 (0.3281-1.07) | 0.62 (0.3-1.2) | 0.95 (0.57-1.6) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | |
| rs17614773 | 1.83 (0.8175-3.0) | 1.18 (0.55-2.4) | 1.49 (0.99-2.6) | 1.31 (0.694) | 2.26 (0.476) | 2.16 (0.473) | 1.65 (0.5529) | 1.39 (0.8642) | 1.34 (0.6991) | 1.94 (0.9393) | 2.71 (0.4819) | 1.33 (0.7424) | 1.63 (0.9462) | 1.62 (0.9232) | 1.65 (0.9409) | 1.32 (0.7332) | 1.29 (0.5246) | 1.16 (0.4684) | 1.23 (0.2125) | 3.92 (0.6403) | 1.78 (0.5626) | 0.92 (0.4173) | 1.66 (0.62) | 1.11 (0.49) | 1.51 (0.6) | 0.91 (0.41) | 0.7 (0.59) | 0.8978 | |
| rs10519067 | 0.66 (0.38-1.13) | 0.78 (0.55-1.4) | 1.08 (0.6482) | 2.08 (1.0504) | 3.3 (0.1504) | 2.3 (0.1057) | 2.38 (0.0616) | 1.59 (0.7738) | 2.29 (0.0768) | 2.47 (0.7939) | 2.21 (0.2072) | 1.05 (0.0821) | 1.26 (0.3522) | 1.70 (0.6116) | 1.19 (0.5549) | 1.72 (0.6745) | 1.64 (0.806) | 1.85 (0.4125) | 1.35 (0.5867) | 1.85 (0.3666) | 1.44 (0.3477) | 0.10 (0.01) | 2.84 (0.0674) | 1.08 (0.0974) | | | | | |
| rs12438866 | 0.56 (0.34-0.95) | 1.2 (0.85-2.1) | 0.73 (0.52-1.3) | 1.03 (0.57-1.8) | 1.03 (0.61-1.8) | 1.06 (0.61-1.9) | 1.07 (0.62-1.9) | 1.06 (0.61-1.9) | 1.06 (0.61-1.9) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | 0.67 (0.25-1.08) | 0.8 (0.53-1.08) | 0.79 (0.52-1.17) | 1.06 (0.66-1.71) | 1.08 (0.66-1.71) | 1.07 (0.66-1.71) | 1.38 (0.75-2.52) | 1.13 (0.75-2.02) | 0.83 (0.52-1.32) | 1.32 (0.83-2.11) | 1.01 (0.48-2.15) | 3.43 (0.86-13.62) | 0.9 (0.48-1.69) | 0.7 (0.59-0.8978) | | | |
| rs93202215 | 1.54 (0.6182-2.8) | 1.81 (0.966-3.2) | 1.19 (0.713-2.0) | 2.32 (0.5366) | 2.26 (0.4405) | 1.24 (0.711) | 1.71 (0.4597) | 1.94 (0.2968) | 1.39 (0.8518) | 2.13 (0.8899) | 2.06 (0.7369) | 1.81 (0.762) | 1.28 (0.5033) | 1.37 (0.7171) | 1.84 (0.1699) | 1.6 (0.8699) | 1.79 (0.2158) | 1.44 (0.5993) | 1.27 (0.6249) | 1.21 (0.3905) | 1.71 (0.2796) | 1.94 (0.0367) | 2.06 (0.2265) | 0.89 (0.116) | 1.66 (0.59) | 1.21 (0.48) | 0.7 (0.59) | 0.8978 | |
| rs17204440 | 1.28 (0.3281-1.07) | 0.62 (0.3-1.2) | 0.95 (0.57-1.6) | 1.11 (0.7-2.0) | 0.88 (0.51-1.5) | 1.09 (0.6482) | 0.93 (0.48-1.4) | 0.92 (0.59-1.4) | 0.99 (0.64-1.5) | 0.99 (0.64-1.5) | 0.83 (0.5-1.4) | 1.24 (0.82-1.82) | 0.87 (0.36-1.21) | | | | | | | | | | | | | | | | |

Supplementary Table S6. Complete replication results of RORA*NPSR1 interactions on nocturnal asthma in BAMSE and MAAS.

effect direction different to MAGIC/ISAAC

effect direction the same as in MAGIC/ISAAC

borderline significant replication

significant replication of interaction on nocturnal asthma

| NPSR1 | RORA | nocturnal asthma | | nocturnal breathing difficulties | | nocturnal symptoms at age 11 | |
|-----------|-------------------------|------------------|---------------|----------------------------------|---------------------|------------------------------|---------------|
| | | (MAGIC/ISAAC) | | (BAMSE) | | (MAAS) | |
| rs2609234 | rs4775289 | 1.92 (1.11-3.32) | 0.0193 | na | | 1.28 (0.74-2.2) | 0.3733 |
| | rs4775292 | 1.78 (1.05-3.01) | 0.0326 | na | | 1.56 (0.86-2.84) | 0.1449 |
| | rs12437690 | 0.56 (0.34-0.95) | 0.031 | na | | 0.69 (0.39-1.23) | 0.2076 |
| | rs7171681 | 1.99 (1.17-3.39) | 0.0117 | na | | 1.72 (0.89-3.32) | 0.1057 |
| | rs341382 | 1.74 (1.03-2.93) | 0.0376 | na | | 1.88 (0.96-3.7) | 0.0675 |
| rs2530547 | rs4775289 | 1.51 (1.03-2.2) | 0.0332 | 0.98 (0.68-1.43) | 0.9296 | 1.37 (0.84-2.22) | 0.2068 |
| | rs12591848 [†] | 0.49 (0.27-0.9) | 0.0216 | 0.77 (0.44-1.32) | 0.3357 [‡] | 1.03 (0.46-2.28) | 0.9504 |
| | rs7171681 | 1.54 (1.01-2.36) | 0.0446 | 1.04 (0.7-1.55) | 0.8428 [‡] | 1.1 (0.61-1.97) | 0.7497 |
| rs1379928 | rs8043356 | 0.41 (0.2-0.87) | 0.0201 | 1 (0.55-1.8) | 0.995 | 0.75 (0.37-1.53) | 0.4323 |
| | rs4775292 | 1.68 (1.08-2.6) | 0.02 | 1.23 (0.76-1.97) | 0.3974 [‡] | 2.11 (1.16-3.84) | 0.0143 |
| | rs12437690 | 0.62 (0.39-0.97) | 0.036 | 0.86 (0.54-1.37) | 0.5355 [‡] | 0.53 (0.3-0.93) | 0.0254 |
| | rs17204454 | 1.59 (1.04-2.43) | 0.0318 | 1.11 (0.71-1.75) | 0.644 [‡] | 1.99 (1.14-3.46) | 0.0149 |
| | rs7171681 | 1.69 (1.06-2.68) | 0.0262 | 1.16 (0.7-1.93) | 0.5688 [‡] | 0.98 (0.52-1.87) | 0.9594 |
| | rs341382 | 1.73 (1.07-2.77) | 0.0243 | 1.27 (0.75-2.16) | 0.3736 [‡] | 1.06 (0.54-2.06) | 0.8696 |
| | rs8042149 | 1.55 (1.01-2.4) | 0.0466 | 0.89 (0.56-1.41) | 0.6139 | 0.99 (0.6-1.62) | 0.9658 |
| | rs4775301 | 1.67 (1.08-2.56) | 0.0199 | 0.96 (0.61-1.52) | 0.8707 | 1 (0.6-1.67) | 0.9961 |
| | rs11071561 | 1.61 (1.03-2.5) | 0.0351 | 0.98 (0.62-1.56) | 0.9332 | 0.87 (0.49-1.55) | 0.635 |
| rs963218 | rs11635314 | 0.57 (0.33-0.98) | 0.0434 | 0.79 (0.47-1.33) | 0.3752 [‡] | 0.79 (0.42-1.51) | 0.48 |
| | rs4775289 | 1.66 (1.15-2.39) | 0.0063 | 1.25 (0.86-1.81) | 0.2393 [‡] | 1.1 (0.71-1.72) | 0.6672 |
| | rs12591848 [†] | 0.46 (0.25-0.84) | 0.0108 | 0.6 (0.35-1.05) | 0.0759 [‡] | 0.77 (0.37-1.6) | 0.4834 |
| | rs7171681 | 1.85 (1.24-2.77) | 0.0028 | 1.23 (0.84-1.8) | 0.2797 [‡] | 1.08 (0.63-1.84) | 0.7787 |
| | rs341382 | 1.8 (1.18-2.75) | 0.0063 | 1.21 (0.82-1.8) | 0.3422 [‡] | 1.4 (0.81-2.43) | 0.2333 |
| | rs4775301 | 1.56 (1.08-2.25) | 0.0173 | 0.92 (0.64-1.31) | 0.6361 | 1 (0.63-1.58) | 0.9862 |
| rs324384 | rs11071561 | 1.51 (1.04-2.19) | 0.0285 | 1.07 (0.75-1.53) | 0.7193 [‡] | 1.22 (0.75-1.97) | 0.4257 |
| | rs2899662 | 0.65 (0.44-0.96) | 0.0317 | 0.97 (0.67-1.41) | 0.8682 [‡] | 0.6 (0.36-0.98) | 0.0395 |
| | rs7171681 | 0.57 (0.37-0.87) | 0.0086 | 0.88 (0.59-1.3) | 0.5256 [‡] | 0.84 (0.49-1.46) | 0.5349 |
| | rs8042149 | 0.6 (0.42-0.86) | 0.0059 | 1.07 (0.75-1.52) | 0.725 | 0.93 (0.6-1.46) | 0.7683 |
| rs324396 | rs4775301 | 0.63 (0.44-0.9) | 0.0116 | 1.01 (0.71-1.45) | 0.9567 | 0.87 (0.55-1.36) | 0.5365 |
| | rs2899662 | 0.61 (0.4-0.95) | 0.0277 | 0.73 (0.49-1.1) | 0.1309 [‡] | 0.48 (0.28-0.82) | 0.0069 |

| | | | | |
|------------|--------------|--------------------------------|---------------------------|-------------------------------|
| | rs7171681 | 0.45 (0.28-0.73) 0.0013 | 0.82 (0.54-1.24) 0.3384 † | 0.54 (0.3-0.99) 0.0459 |
| | rs341382 | 0.52 (0.32-0.85) 0.0094 | 0.9 (0.58-1.4) 0.649 † | 0.58 (0.31-1.07) 0.0825 |
| | rs8042149 | 0.62 (0.42-0.92) 0.0165 | 0.91 (0.62-1.33) 0.6339 † | 0.68 (0.42-1.1) 0.1122 |
| | rs4775301 | 0.65 (0.44-0.96) 0.0307 | 0.87 (0.6-1.28) 0.4886 † | 0.63 (0.38-1.03) 0.065 |
| rs324957 | rs2899662 | 0.65 (0.44-0.96) 0.032 | na | 0.56 (0.34-0.91) 0.02 |
| | rs7171681 | 0.55 (0.36-0.84) 0.006 | na | 0.8 (0.46-1.39) 0.4285 |
| | rs8042149 | 0.62 (0.43-0.89) 0.0101 | na | 0.84 (0.54-1.32) 0.4562 |
| | rs4775301 | 0.65 (0.46-0.94) 0.0202 | na | 0.78 (0.5-1.23) 0.2826 |
| rs1419779 | rs11635314 | 0.52 (0.29-0.93) 0.0273 | na | 0.69 (0.37-1.3) 0.2551 |
| | rs4775289 | 1.6 (1.09-2.32) 0.015 | na | 1.17 (0.74-1.85) 0.5094 |
| | rs2899662 | 1.49 (1.01-2.2) 0.0438 | na | 1.16 (0.71-1.91) 0.5523 |
| | rs12591848 † | 0.34 (0.17-0.68) 0.002 | na | 0.65 (0.32-1.34) 0.2474 |
| | rs7171681 | 1.71 (1.14-2.55) 0.009 | na | 0.9 (0.51-1.58) 0.7031 |
| | rs341382 | 1.54 (1.01-2.35) 0.0448 | na | 1.09 (0.61-1.94) 0.7805 |
| | rs8042149 | 1.59 (1.09-2.32) 0.0165 | na | 0.9 (0.57-1.43) 0.6584 |
| | rs4775301 | 1.81 (1.23-2.65) 0.0024 | na | 0.9 (0.56-1.45) 0.67 |
| | rs11071561 | 1.57 (1.07-2.29) 0.021 | na | 0.92 (0.55-1.52) 0.7322 |
| rs324981 | rs8042149 | 1.63 (1.15-2.31) 0.0058 | na | 1.21 (0.79-1.84) 0.3789 |
| | rs4775301 | 1.61 (1.14-2.27) 0.0072 | na | 1.19 (0.78-1.82) 0.4243 |
| | rs11071561 | 1.51 (1.07-2.13) 0.02 | na | 1.57 (0.99-2.5) 0.0577 |
| rs325462 | rs7171681 | 0.65 (0.43-0.98) 0.0408 | na | 0.77 (0.46-1.29) 0.3274 |
| | rs8042149 | 0.64 (0.45-0.91) 0.0139 | na | 0.87 (0.56-1.34) 0.5197 |
| | rs4775301 | 0.65 (0.46-0.93) 0.0183 | na | 0.87 (0.56-1.35) 0.542 |
| rs34705969 | rs11635314 | 6.33 (1.15-34.83) 0.034 | 1.87 (0.63-5.61) 0.2613 † | 0.43 (0.06-2.87) 0.385 |
| | rs9302215 | 3.15 (1.07-9.27) 0.0367 | 0.8 (0.28-2.28) 0.6817 | 0.69 (0.19-2.54) 0.5802 |
| | rs7164773 | 0.29 (0.09-0.87) 0.0277 | 0.62 (0.22-1.7) 0.35 † | 0.96 (0.19-4.72) 0.955 |
| | rs341459 | 3.06 (1.04-8.94) 0.0413 | 0.73 (0.26-2.06) 0.5498 | 1.18 (0.28-4.95) 0.8239 |
| rs6972158 | rs11635314 | 0.5 (0.27-0.93) 0.0282 | 0.7 (0.4-1.23) 0.2181 † | 1.25 (0.67-2.32) 0.4849 |
| | rs4775292 | 1.59 (1.06-2.4) 0.0262 | 1.19 (0.8-1.77) 0.4038 † | 0.8 (0.49-1.32) 0.3871 |
| | rs17204367 | 0.62 (0.42-0.92) 0.0173 | 0.9 (0.59-1.37) 0.6269 † | 1.15 (0.72-1.82) 0.5611 |
| | rs12437690 | 0.65 (0.44-0.96) 0.0301 | 0.89 (0.61-1.31) 0.5593 † | 1.29 (0.81-2.07) 0.2886 |
| | rs9302215 | 0.59 (0.39-0.89) 0.0116 | 0.9 (0.61-1.33) 0.5844 † | 1.28 (0.8-2.05) 0.2977 |
| | rs2899662 | 1.51 (1-2.28) 0.0498 | 1.21 (0.82-1.81) 0.3401 † | 1.12 (0.68-1.85) 0.6528 |
| | rs10162630 | 0.67 (0.45-1) 0.0488 | 1.03 (0.71-1.51) 0.871 | 0.95 (0.59-1.5) 0.8124 |
| | rs7171681 | 1.72 (1.1-2.69) 0.0181 | 1.19 (0.78-1.8) 0.4184 † | 0.82 (0.47-1.45) 0.4976 |
| | rs341382 | 1.7 (1.08-2.67) 0.0215 | 1.35 (0.87-2.09) 0.174 † | 0.93 (0.52-1.65) 0.7967 |
| | rs6494229 | 1.56 (1.07-2.27) 0.0207 | 0.84 (0.57-1.22) 0.3518 | 0.75 (0.45-1.23) 0.2505 |
| rs714588 | rs4775289 | 1.61 (1.13-2.29) 0.008 | 0.86 (0.59-1.24) 0.4167 | 1.02 (0.65-1.61) 0.929 |

| | | | | |
|-----------|--------------|--------------------------------|---------------------------|-------------------------|
| rs887020 | | 1.53 (1.06-2.23) 0.0249 | 1.11 (0.76-1.63) 0.5807 † | 0.99 (0.64-1.54) 0.9759 |
| rs740347 | | 1.67 (1.02-2.73) 0.041 | 1.65 (0.97-2.8) 0.0646 † | 1.03 (0.56-1.92) 0.9164 |
| rs1345267 | | 0.63 (0.44-0.91) 0.0145 | na | 0.84 (0.53-1.33) 0.4518 |
| rs323922 | rs10162630 | 0.66 (0.45-0.95) 0.0246 | 0.87 (0.61-1.24) 0.4534 † | 0.74 (0.48-1.14) 0.1743 |
| rs714588 | | 0.53 (0.29-0.98) 0.0415 | 0.66 (0.38-1.16) 0.1465 † | 0.98 (0.46-2.09) 0.958 |
| rs887020 | rs12591848 † | 0.44 (0.24-0.81) 0.0089 | 0.71 (0.4-1.25) 0.2323 † | 0.82 (0.37-1.8) 0.615 |
| rs740347 | rs7171681 | 1.81 (1.06-3.09) 0.0309 | 1.71 (0.99-2.95) 0.0546 † | 0.75 (0.35-1.64) 0.4749 |
| rs323922 | rs8042149 | 1.51 (1.06-2.17) 0.0234 | 0.89 (0.62-1.28) 0.5417 | 1.22 (0.79-1.88) 0.381 |

Supplementary Table S7. Validation of RORA*NPSR1 interaction results on nocturnal asthma in MAAS at age 16.

effect direction different than at age 11
 effect direction the same as at age 11
 borderline significant validation
 significant validation of interaction effect on nocturnal asthma at age 16

| <i>NPSR1</i> | <i>RORA</i> | Nocturnal symptoms at age 11 (MAAS) | Nocturnal symptoms at age 16 (MAAS) |
|--------------|-------------|----------------------------------------|----------------------------------------|
| rs2609234 | rs341382 | 1.88 (0.96-3.7) 0.0675 | 1.84 (0.76-4.42) 0.1747 |
| rs1379928 | rs4775292 | 2.11 (1.16-3.84) 0.0143 | 2.34 (1-5.49) 0.0505 |
| | rs12437690 | 0.53 (0.3-0.93) 0.0254 | 0.86 (0.4-1.83) 0.6917 |
| | rs17204454 | 1.99 (1.14-3.46) 0.0149 | 1.87 (0.87-4.01) 0.11 |
| rs324384 | rs2899662 | 0.6 (0.36-0.98) 0.0395 | 0.55 (0.28-1.1) 0.0912 |
| rs324396 | rs2899662 | 0.48 (0.28-0.82) 0.0069 | 0.4 (0.18-0.86) 0.0194 |
| | rs7171681 | 0.54 (0.3-0.99) 0.0459 | 0.48 (0.2-1.12) 0.0901 |
| | rs341382 | 0.58 (0.31-1.07) 0.0825 | 0.38 (0.15-0.95) 0.0384 |
| | rs4775301 | 0.63 (0.38-1.03) 0.065 | 0.83 (0.4-1.71) 0.6142 |
| rs324957 | rs2899662 | 0.56 (0.34-0.91) 0.02 | 0.53 (0.26-1.05) 0.0675 |
| rs324981 | rs11071561 | 1.57 (0.99-2.5) 0.0577 | 1.3 (0.69-2.46) 0.4219 |

Supplementary Table S8. Interaction results of RORA * NPSR1-SNPs on asthma without nocturnal symptoms in MAGICS/ISAAC.

Table with columns for RORA SNPs (rs2609234 to rs1071561) and NPSR1 SNPs (rs1452571 to rs6972158). Each cell contains a numerical value representing the interaction result.

Supplementary Table S9. Complete replication results of RORA*NPSR1 interactions on asthma without nocturnal symptoms in BAMSE and MAAS.

| |
|-----------------------------------------------------------------------------|
| effect direction different to MAGICS/ISAAC |
| effect direction the same as in MAGICS/ISAAC |
| borderline significant replication |
| significant replication of interaction on asthma without nocturnal symptoms |

| NPSR1 | RORA | asthma w/o nocturnal symptoms | asthma w/o nocturnal symptoms | asthma w/o nocturnal symptoms |
|------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|
| | | (MAGICS) | (BAMSE) | (MAAS) |
| rs323917 | rs4775292 | 0.45 (0.22-0.93) 0.0318 | 0.71 (0.28-1.82) 0.4774 | 0.84 (0.28-2.55) 0.7638 |
| | rs17204395 | 2.74 (1.11-6.75) 0.0285 | na | 1.23 (0.35-4.27) 0.7485 |
| | rs9302215 | 2.05 (1.04-4.03) 0.037 | 0.64 (0.25-1.65) 0.3562 | 1.03 (0.35-3.07) 0.9555 |
| | rs17204440 | 2.22 (1.11-4.43) 0.0234 | na | 1.51 (0.52-4.42) 0.4493 |
| | rs7164773 | 0.48 (0.24-0.93) 0.0304 | 0.79 (0.31-1.98) 0.6152 | 1.08 (0.37-3.22) 0.8841 |
| | rs12438866 | 2.52 (1.23-5.16) 0.0117 | 2.37 (1-5.61) 0.0491 | 1.42 (0.51-4) 0.5036 |
| | rs17204454 | 0.29 (0.13-0.61) 0.0012 | 0.66 (0.27-1.63) 0.3654 | 0.6 (0.2-1.82) 0.3702 |
| | rs2899662 | 0.27 (0.12-0.61) 0.0016 | 1.01 (0.43-2.35) 0.9871 | 0.84 (0.28-2.53) 0.751 |
| rs1345267 | rs10162630 | 2.43 (1.16-5.08) 0.0187 | 1.57 (0.68-3.61) 0.2899 | 1.32 (0.48-3.67) 0.592 |
| | rs7173227 | 1.71 (1.06-2.77) 0.0292 | na | 1.49 (0.81-2.75) 0.197 |
| | rs10162630 | 0.65 (0.47-0.9) 0.0087 | na | 0.77 (0.49-1.23) 0.2743 |
| rs324396 | rs6494229 | 1.38 (1.01-1.88) 0.0416 | na | 1.08 (0.68-1.72) 0.749 |
| | rs2899662 | 0.66 (0.45-0.96) 0.0288 | 0.93 (0.62-1.38) 0.7193 | 0.69 (0.41-1.15) 0.1581 |
| | rs8042149 | 0.59 (0.41-0.83) 0.0028 | 0.9 (0.6-1.33) 0.586 | 0.88 (0.54-1.43) 0.6104 |
| | rs4775301 | 0.61 (0.43-0.87) 0.0058 | 0.93 (0.62-1.39) 0.7257 | 0.76 (0.47-1.24) 0.277 |
| rs740347 | rs11071561 | 0.64 (0.45-0.93) 0.0191 | 1.24 (0.83-1.86) 0.2893 | 0.74 (0.44-1.22) 0.2379 |
| | rs2899662 | 1.54 (1.02-2.34) 0.0397 | 1.09 (0.66-1.79) 0.7492 | 1.01 (0.53-1.93) 0.9664 |
| rs727162 | rs17204367 | 0.66 (0.44-0.97) 0.0344 | 1.08 (0.67-1.73) 0.7662 | 0.92 (0.53-1.6) 0.7766 |
| | rs17204395 | 0.48 (0.27-0.86) 0.0138 | na | 0.92 (0.46-1.83) 0.814 |
| | rs9302215 | 0.59 (0.39-0.9) 0.0135 | 1.02 (0.65-1.6) 0.9486 | 1.08 (0.64-1.84) 0.7676 |
| | rs17204440 | 0.59 (0.41-0.87) 0.0073 | na | 0.86 (0.51-1.46) 0.5808 |
| | rs2899662 | 1.49 (1.03-2.14) 0.034 | 0.9 (0.56-1.43) 0.643 | 0.9 (0.52-1.54) 0.6923 |
| | rs341459 | 0.55 (0.35-0.86) 0.0083 | 1.05 (0.67-1.63) 0.8467 | 1.1 (0.62-1.95) 0.7516 |
| | rs10162630 | 0.63 (0.43-0.9) 0.0128 | 1.01 (0.65-1.58) 0.9579 | 1.25 (0.73-2.14) 0.4074 |
| | rs6494229 | 1.54 (1.06-2.23) 0.0229 | 1.04 (0.65-1.66) 0.8829 | 1.23 (0.71-2.15) 0.4599 |
| | rs4775301 | 1.49 (1.04-2.14) 0.0298 | 0.96 (0.6-1.54) 0.8702 | 1.54 (0.88-2.72) 0.1331 |
| rs11071561 | 1.56 (1.07-2.28) 0.0198 | 0.95 (0.6-1.49) 0.8132 | 1.5 (0.85-2.66) 0.1637 | |

Supplementary Table S10. Interactions between RORA and NPSR1 on severe asthma in MAGICS/ISAAC


Table with 25 columns (rsIDs) and 25 rows (rsIDs). The top row is labeled 'NPSR1' and the leftmost column is labeled 'RORA'. The table contains numerical values representing interactions, with some cells containing bolded text indicating significant findings.

Supplementary Table S11. Complete replication results of interaction effects between *RORA* and *NPSR1* on asthma severity.


| | |
|-----------------------------------------------------------------------------|--|
| effect direction different to MAGICS/ISAAC | |
| effect direction the same as in MAGICS/ISAAC | |
| borderline significant replication | |
| significant replication of interaction on asthma without nocturnal symptoms | |

| <i>NPSR1</i> | <i>RORA</i> | Number of doctor and ED visits | Poor asthma control | Number of exacerbations |
|--------------|-------------|--------------------------------|----------------------|-------------------------|
| | | (MAGICS/ISAAC) | (BAMSE) | (MAAS) |
| rs2609234 | rs11635314 | -0.83 (-0.27) 0.0018 | na | 0.26 (0.2) 0.2011 |
| | rs4775289 | 0.45 (0.18) 0.012 | na | -0.07 (-0.14) 0.6233 |
| | rs4775292 | 0.43 (0.18) 0.0153 | na | 0 (-0.16) 0.9928 |
| | rs12437690 | -0.51 (-0.18) 0.0039 | na | 0.11 (0.15) 0.4558 |
| rs714588 | rs4775289 | 0.4 (0.14) 0.0037 | -0.17 (-0.33) 0.6054 | -0.11 (-0.11) 0.323 |
| | rs4775292 | 0.29 (0.14) 0.0391 | 0.47 (0.37) 0.2067 | -0.02 (-0.11) 0.8475 |
| | rs17204454 | 0.26 (0.13) 0.0497 | 0.43 (0.36) 0.2217 | 0.13 (0.11) 0.243 |
| rs1963499 | rs4775289 | 0.82 (0.29) 0.0047 | -0.96 (-0.63) 0.1286 | -0.12 (-0.17) 0.48 |
| | rs17191596 | 1.86 (0.59) 0.0016 | -1.73 (-0.8) 0.0297 | -0.17 (-0.26) 0.5235 |
| | rs10152719 | -0.69 (-0.3) 0.0197 | 1.06 (0.82) 0.1929 | 0.3 (0.24) 0.2146 |
| rs2168890 | rs4775289 | 0.63 (0.21) 0.002 | -0.88 (-0.63) 0.1617 | -0.07 (-0.16) 0.6531 |
| | rs17204395 | 0.48 (0.24) 0.0486 | na | -0.14 (-0.21) 0.5102 |
| rs2530547 | rs8024629 | 0.44 (0.19) 0.0208 | -0.07 (-0.67) 0.9138 | -0.09 (-0.15) 0.563 |
| | rs4775289 | 0.53 (0.14) 0.0002 | -0.04 (-0.45) 0.9284 | -0.1 (-0.12) 0.3726 |
| | rs341392 | -0.38 (-0.18) 0.0382 | 0.06 (0.5) 0.8982 | 0.06 (0.14) 0.6823 |
| rs887020 | rs17191582 | 0.45 (0.2) 0.026 | -0.14 (-0.7) 0.8378 | -0.14 (-0.16) 0.383 |
| | rs8024629 | 0.55 (0.18) 0.0017 | -0.3 (-0.68) 0.6623 | -0.03 (-0.14) 0.8144 |
| | rs17191596 | 0.51 (0.22) 0.0228 | -0.29 (-0.7) 0.6799 | -0.1 (-0.16) 0.5126 |
| | rs4775292 | 0.36 (0.14) 0.0095 | 0.25 (0.57) 0.6614 | 0.04 (0.11) 0.7376 |
| rs1379928 | rs4775289 | 0.39 (0.16) 0.0166 | -0.25 (-0.44) 0.5605 | -0.03 (-0.13) 0.7939 |
| | rs4775292 | 0.34 (0.16) 0.0303 | 0.49 (0.54) 0.3648 | -0.09 (-0.14) 0.5139 |
| rs963218 | rs4775289 | 0.34 (0.13) 0.0122 | -0.15 (-0.49) 0.7628 | -0.17 (-0.1) 0.1124 |
| | rs17237367 | -0.35 (-0.17) 0.0334 | 0.38 (0.38) 0.3209 | 0.05 (0.13) 0.7366 |
| rs2609215 | rs17191582 | 1.09 (0.39) 0.0058 | na | -0.41 (-0.26) 0.1165 |
| | rs8024629 | 0.83 (0.35) 0.0184 | -0.2 (-0.92) 0.8315 | -0.16 (-0.22) 0.4805 |
| | rs4775289 | 0.59 (0.24) 0.0135 | -0.77 (-0.46) 0.096 | -0.08 (-0.18) 0.6824 |
| | rs17191596 | 0.94 (0.41) 0.0209 | -0.17 (-0.94) 0.8589 | -0.11 (-0.25) 0.6645 |


| | | | | |
|-----------|------------|-----------------------------|---------------------------|----------------------|
| | rs17204395 | 0.78 (0.31) 0.0123 | 0.21 (1.03) 0.8344 | -0.06 (-0.23) 0.7982 |
| | rs6494229 | -0.66 (-0.25) 0.0099 | 0.22 (0.66) 0.7405 | 0.1 (0.2) 0.6117 |
| rs323917 | rs17191582 | 1.31 (0.54) 0.0144 | na | -0.21 (-0.31) 0.504 |
| | rs17191596 | 1.43 (0.58) 0.0135 | na | -0.01 (-0.31) 0.971 |
| rs324384 | rs17237367 | 0.33 (0.16) 0.0457 | 0.22 (0.46) 0.6256 | 0.01 (0.13) 0.9436 |
| rs324396 | rs4775301 | -0.29 (-0.15) 0.0437 | -0.57 (-0.6) 0.3435 | -0.01 (-0.12) 0.9631 |
| rs740347 | rs4775289 | 0.5 (0.18) 0.006 | 0 (-0.54) 0.9987 | -0.21 (-0.16) 0.1822 |
| | rs17237367 | -0.58 (-0.22) 0.0087 | 0.77 (0.43) 0.0722 | -0.25 (-0.21) 0.235 |
| rs1419779 | rs12899193 | 0.33 (0.16) 0.0386 | na | -0.03 (-0.12) 0.8112 |
| | rs8024629 | 0.35 (0.18) 0.0442 | na | -0.1 (-0.14) 0.475 |
| | rs4775289 | 0.43 (0.14) 0.0015 | na | -0.12 (-0.11) 0.2999 |
| | rs17237367 | -0.46 (-0.17) 0.0085 | na | 0.02 (0.15) 0.8908 |
| | rs4775301 | 0.31 (0.14) 0.0271 | na | -0.03 (-0.12) 0.825 |
| rs324981 | rs8042149 | 0.32 (0.14) 0.0203 | 0.79 (0.46) 0.0884 | -0.03 (-0.1) 0.7405 |
| | rs4775301 | 0.3 (0.14) 0.0266 | 1.01 (0.43) 0.0204 | -0.03 (-0.11) 0.7607 |
| | rs11071561 | 0.3 (0.14) 0.0285 | 0.86 (0.67) 0.2016 | 0.09 (0.11) 0.4195 |
| rs6972158 | rs17204440 | -0.35 (-0.14) 0.0126 | na | 0 (0.11) 0.9764 |
| | rs12438866 | -0.28 (-0.14) 0.0493 | 0.55 (0.42) 0.1939 | -0.11 (-0.12) 0.3694 |
| | rs17204454 | 0.28 (0.14) 0.0431 | -0.46 (-0.42) 0.2733 | 0 (0.12) 0.9978 |
| | rs2899662 | 0.3 (0.14) 0.0382 | -0.28 (-0.43) 0.5126 | 0.02 (0.12) 0.8742 |
| | rs10162630 | -0.37 (-0.14) 0.0073 | 0.04 (0.37) 0.908 | -0.13 (-0.11) 0.2604 |
| | rs7171681 | 0.32 (0.15) 0.0318 | -0.17 (-0.49) 0.7279 | -0.05 (-0.12) 0.682 |
| | rs10152719 | -0.37 (-0.18) 0.0413 | -0.62 (-0.54) 0.2561 | 0.08 (0.16) 0.621 |
| | rs341392 | -0.46 (-0.17) 0.0078 | -0.71 (-0.46) 0.1237 | 0.06 (0.13) 0.6587 |
| | rs11071561 | 0.29 (0.14) 0.0416 | -0.24 (-0.49) 0.6223 | 0.06 (0.12) 0.6222 |




48x24mm (300 x 300 DPI)




190x85mm (300 x 300 DPI)



127x102mm (300 x 300 DPI)



169x116mm (300 x 300 DPI)



127x97mm (300 x 300 DPI)